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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the
progressive degeneration of motor neurons. Rho Guanine Nucleotide Exchange factor (RGNEF),
like other RNA-binding proteins, has been observed to form inclusions in the spinal cord motor
neurons of both sporadic and familial cases of ALS. RGNEF has been determined to be a prosurvival factor under stress conditions. When comparing expression of different constructs of
RGNEF in HEK293T cells, a Leucine-rich domain containing fragment of RGNEF (L-Rich),
was found to form aggregates under metabolic stress that co-aggregated with TDP-43, another
ALS-linked RNA-binding protein.
In this thesis, I used both in vivo and in vitro techniques to further characterize the role of
L-Rich in the pro-survival effect of RGNEF. In vitro analysis examined whether L-Rich was
needed against osmotic or oxidative stress for improved cell survival. Immunofluorescence
determined whether RGNEF, RGNEF lacking the Leucine-rich domain (RGNEFΔL), or L-Rich
alone were capable of colocalizing with TDP-43 positive granules following stress.
Immunoprecipitation examined whether the Leucine-rich domain was essential for the
interaction between RGNEF and TDP-43. A Drosophila model was included to examine the
impact of L-Rich in modulating the toxic effect of human wildtype TDP-43 in Drosophila. My
findings support the hypothesis that L-Rich of RGNEF is important in the cytoprotective effect
of full length RGNEF in vitro. This effect varies depending on the type of cellular insult present.
My findings also support the hypothesis that L-Rich of RGNEF is a protective modifier of TDP43 toxicity in Drosophila.

Keywords
Amyotrophic Lateral Sclerosis, RGNEF, TDP-43, Leucine-rich domain, HEK293T cells,
Drosophila, Cytotoxicity assay, Immunofluorescence, Immunoprecipitation, UAS-GAL4.
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Chapter 1
1 Thesis Rationale/ Overview
ALS is a neurodegenerative disease characterized by the progressive loss of upper and lower
motor neurons (Rowland and Shneider, 2001; Strong, 2010). It is a fatal disease with an average
3-5 year life span post-diagnosis (Strong et al., 2005). The participation of several genes and the
involvement of several cellular processes in the disease process has made it difficult to generate
an effective treatment. In recent years it has become clear that RNA metabolism plays a central
role in the etiology of the pathology of the disease. While RNA binding proteins appear to form
extensive neuronal cytoplasmic inclusions (NCIs) in motor neurons of ALS patients, it remains
unclear how these inclusions form, and what, if any purpose they serve. Recently, we described
an RNA binding protein called Rho Guanine Nucleotide Exchange Factor (RGNEF) that, akin to
other RNA binding proteins, has been observed to co-localize with NCIs in the spinal cord
neurons of both sporadic and familial cases of ALS (Droppelmann et al., 2013a; Keller et al.,
2012) RGNEF has also been observed to co-aggregate with TAR DNA binding protein of 43
kDa (TDP-43; another RNA binding protein with genetic mutations in 5% of familial ALS cases
and showing inclusions/ proteinopathy in 95% of ALS cases) in NCIs in spinal cord motor
neurons of ALS patients (Droppelmann et al., 2013a; Keller et al., 2012)
RGNEF is unique in its structure and function when compared to other ALS-related RNA
binding proteins. It contains an amino-terminal Leucine-rich domain, a zinc-finger (Zn) domain,
a guanine exchange factor (GEF) domain, a pleckstrin homology (PH) domain, and a carboxyl
terminal RNA-binding domain (RBD). RGNEF is the first known ALS-related RNA binding
protein to have a dual function as a guanine exchange factor (Droppelmann et al., 2013b). Unlike
other ALS-related RNA binding proteins, RGNEF has been determined to be a survival factor
under both oxidative and osmotic stress conditions (Cheung et al., 2017).
Neurotoxicity is a common feature of TDP-43 in ALS, with overexpression of wild type
or mutant TDP-43 producing consistently rapid cell death in a diverse range of animal models
(as reviewed in (Wegorzewska and Baloh, 2011)). Given the evidence that RGNEF co-localizes
with and immuno-precipitates TDP-43 (Keller et al., 2012), the pro-survival effect of RGNEF
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may extend to combat TDP-43 neurotoxicity, though to date this possibility has yet to be
investigated.
Recent work has suggested that the amino-terminal Leucine-rich domain may play a
critical role in RGNEF’s pro-survival activity (Cheung et al., 2017). When compared to different
truncation constructs of RGNEF, the absence of the Leucine-rich domain removed the
cytoprotective effect of RGNEF under osmotic stress but not oxidative stress. It remains to be
determined whether absence of this domain would also remove the potential protective effect of
RGNEF against TDP-43 toxicity. In addition, it remains to be determined whether the Leucinerich domain is capable of a protective effect on its own and whether it alone can influence TDP43 toxicity. I hypothesize that the Leucine-rich domain alone is protective against cellular stress
alone, and that this protective effect persists towards TDP-43, reducing its toxicity.
To test this, the survival of HEK293T cells expressing an amino-terminal fragment of
RGNEF containing the Leucine-rich domain (L-Rich), full length RGNEF, or RGNEF lacking
the Leucine-rich domain (RGNEFΔL) under stress conditions known to alter TDP-43’s
localization was examined. Interaction and co-localization between RGNEF and TDP-43 via
immunoprecipitation and immunofluorescence were also examined.
In parallel, transgenic flies bearing human wildtype TDP-43 and RGNEF, either
separately, or co-expressed, were established and characterized using the GAL4-UAS expression
system. Survival, motility and eye phenotypes of single transgenic lines expressing human wildtype TDP-43, or L-Rich, were compared to double transgenic lines expressing wild-type TDP-43
and L-Rich together. Non-expressing, single and double transgenic flies, as well as flies
containing only the Gal4 drivers served as controls.
My data will help clarify the function of L-Rich and investigate the relationship of
RGNEF against TDP-43 toxicity in an in vivo model system. By understanding the relationship
of L-Rich and TDP-43, we may discover the minimal protective unit of RGNEF and therefore a
potential therapeutic target for a future treatment of this devastating disease.
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1.1

Amyotrophic Lateral Sclerosis

ALS, also known as Motor Neuron Disease or Lou Gehrig’s disease, is a neurodegenerative
disease that selectively targets upper and lower motor neurons (Rowland and Shneider, 2001;
Strong, 2010). There is currently no treatment that will halt disease progression. Riluzole, a drug
that blocks presynaptic glutamine, is the only FDA approved drug on the market, with minimal
beneficial effect (Miller et al., 2012). ALS Incidence rates are approximately 2.2 per 100,000
worldwide (Chio et al., 2013), with the average age of onset being between 50 to 60 years of age.
Most individuals do not live more than 5 years post-diagnosis (Strong et al., 2005). 90% of cases
are considered sporadic, with no known family history of the disease prior to onset. The
remaining 10% are referred to as familial, meaning there has been another relative affected by
the disease in the family. Disease onset varies between individuals but can be divided broadly
into two groups: spinal onset with symptoms beginning in the upper or lower limbs, and bulbar
onset which can manifest as impaired swallowing and speech production. Almost all skeletal
muscles are eventually affected and patients commonly die from respiratory failure (Al-Chalabi
and Hardiman, 2013).
1.1.2 Genetics of ALS
Originally coined “la sclérose amyotrophique” by Jean-Martin Charcot in 1869, it was not until
1993 that mutations were first linked to the disease. The superoxide dismutase enzyme (SOD1),
responsible for helping manage free radical species in the cell, was observed to have mutations in
familial ALS patients (Rosen et al., 1993). Since then, 20% of familial and 2-7% of sporadic
ALS cases have been discovered to have mutations in SOD1 (Pasinelli and Brown, 2006; Saccon
et al., 2013). On top of this, approximately 30 genes have been found to have mutations in ALS
with another 126 having an association or relationship to the disease (Wroe et al., 2008). The
functions of the products of these genes have widespread effects, leading researchers to now
consider ALS an oligogenic, multi-systems disorder (Bury et al., 2016; Chio et al., 2012;
Droppelmann et al., 2013b; Kenna et al., 2013; Lattante et al., 2012; Strong, 2017; van
Blitterswijk et al., 2012).

Driven by the discovery of these mutations, researchers now seek to uncover the
molecular underpinnings of the disease; the aim being to better understand which processes were
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affected by these mutations and uncover potential biomarkers and therapeutic targets. So far,
some of the gene products have been observed to induce ALS-like pathology on their own while
others have been found to alter the severity of other ALS related proteins (Maurel et al., 2018;
Zhan et al., 2013).
Of interest, several of the proteins observed to bear mutations in ALS are key proteins
involved with RNA metabolism processes including: angiogenin (ANG), ataxin 2 (ATXN2),
heterogenous nuclear ribonucleoprotein (hnRNPA1/A2/B1), TAR-DNA binding protein of 43
kDa (TDP-43), Ewing sarcoma breakpoint region 1 (EWSR1), Fused in sarcoma/translocated in
liposarcoma (FUS/TLS), Matrin 3 (MATR3), TATA-box binding protein associated factor 15
(TAF15), senataxin (SETX), and Rho guanine nucleotide exchange factor (RGNEF) (see Table
1), suggesting that RNA metabolic dysregulation may be central to the disease process. TDP-43
and RGNEF are RNA binding proteins that are central to this thesis and will be described in
more detail below.
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Table 1: RNA-Binding proteins with mutations in ALS
Gene

Protein

Inheritance

Locus

Function

Reference

SETX

Senataxin

AR

9q34.13

DNA/RNA

(Chance et al.,

processing

1998; Chen et
al., 2004)

TAF15

TAF15 RNA

AD

polymerase II,

17q11.1-

DNA/RNA

(Hand et al.,

q11.2

processing

2002; Ticozzi

TATA box dining

et al., 2011)

protein (TDP)associated factor
ANG

Angiogenin,

AD,

ribonuclease,

Sporadic

14q11.1

DNA/RNA

(Greenway et

processing

al., 2004)

DNA/RNA

(Arai et al.,

processing

2006; Kabashi

RNase A family
TARDBP

TAR DNA

AD

1p36.22

binding protein
43 kDa
FUS

Fused in Sarcoma

et al., 2008)
AD/ AR

16q11.2

RNA binding

(Kwiatkowski

protein, DNA

et al., 2009;

repair, exon

Mackenzie et

splicing

al., 2010;
Vance et al.,
2009)

ATXN2

Ataxin-2

AD

12q23q24.1

Oxidative stress

(Borghero et
al., 2015;
Elden et al.,
2010)
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HNRNPA
1/A2B1

Heterogenous

AD

12q13.1

nuclear

mRNA

(Benatar et

processing

al., 2013; Kim

ribonucleoprotein
ARHGEF
28

Rho guanine

et al., 2013)
AD

5q13.2

RNA stability

(Droppelmann

nucleotide

et al., 2013b;

exchange factor

Ma et al.,

28

2014; Zhang
et al., 2016)

MATR3

Matrin 3

AD

5q31.2

Nuclear Matrix
RNA/DNA
binding protein

AR: autosomal recessive; AD: autosomal dominant

(Johnson et
al., 2014)
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1.1.3 ALS Pathology
ALS affects the nervous system, with pathology found in brain and spinal cord, as well as at
cortical and subcortical levels (Strong, 2017). Adding to the multi-systems perception of ALS,
there has thus far been evidence of glial abnormalities, gap junction abnormalities, impeded
axonal transport, glutamic excitotoxicity, mitochondrial dysfunction resulting in oxidative stress,
endoplasmic reticular stress, as well as hyper-ubiquitination and disrupted proteomic clearance in
ALS tissue (Bergeron et al., 1994b; Breuer et al., 1987; Bruijn et al., 2004; Turner et al., 2004;
Wootz et al., 2004). It remains unclear whether these disrupted processes share a common origin
or not. One consistent observation is that TDP-43 re-localizes from the nucleus to the cytosol,
where it is permanently sequestered. This is easily detectable in 97% of ALS cases, regardless of
mutation status of the gene encoding TDP-43 (TARDBP) (Ling et al., 2013; Neumann et al.,
2006).
There is also evidence of neurofilament disruption, with a down regulation of the low
molecular weight neurofilament (NEFL) mRNA steady state levels observed in ALS (Bergeron
et al., 1994a). This is thought to affect the stoichiometry of the 3 neurofilament subunits, termed
low-, medium- and high-molecular weight neurofilaments (NFL, NFM and NFH, respectively).
The purpose of these subunits is to act alongside microtubules to form the neuronal cytoskeleton.
In vivo models in which their stoichiometry has been disrupted demonstrate the formation of
aggregates containing neurofilament protein, suggesting that proper stoichiometry is important
for normal cytoskeletal architecture in neurons (Li et al., 2006).
Further experiments have shown these intraneuronal aggregates to be composed of
multiple proteins. Immunocytochemistry has detected RGNEF, TDP-43, FUS/TLS, ubiquitin
and p62 in the same aggregate formations (Droppelmann et al., 2013a; Keller et al., 2012). This
suggests that aggregation may not be specific to only one protein but may in fact be due to a
common mechanism dictated by the properties of the proteins involved. One theory involves the
association of highly disordered domains of different proteins allowing for a fluid phase change
resulting in local condensations and formation of insoluble aggregates (Molliex et al., 2015).
Recent publications have identified these domains in a wide variety of proteins, including those
found in NCIs in ALS. TDP-43 and FUS/TLS both harbor prion-like domains leading these
proteins to be highly aggregate prone. Interestingly, both proteins are heavily involved in RNA
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metabolism and are RNA binding proteins, suggesting that ALS may be a disease of
dysregulation of RNA.

1.2

RNA metabolism

RNA are ribonucleic acid macromolecules that function as carriers of translatable information as
well as regulators and modifiers of cellular processes. Pre-messenger RNAs (pre-mRNA) are
actively transcribed from genomic DNA, immediately bound by RNA binding proteins and then
subjected to splicing events to form the mature messenger RNA (mRNA). This is then exported
from the nucleus and shuttled to the location within the cell at which translation occurs to
produce one or more copies of proteins encoded by the gene originally transcribed. Following
this, the mRNA is typically degraded. Each of these steps involves a distinct population of RNA
binding proteins, which are still in the process of being deciphered and understood.
1.2.1 RNA Binding Proteins
RNA binding proteins associate with RNA from the time it is transcribed until its degradation.
RNA binding proteins are subdivided into four RNA binding domain families: those that contain
an RNA recognition motif (RRM) a Zinc finger motif, a K-Homology (KH) domain, or a double
stranded RNA binding motif (Banerjee and Barraud, 2014; Clery et al., 2008; Nicastro et al.,
2015; Wolfe et al., 2000). RNA binding proteins bind to double stranded and single stranded
RNA species to guide the formation of ribonucleoprotein complexes, edit RNA transcripts,
shuttle mRNA to and from the nucleus, assist in polyadenylation, and act as mRNA stability
factors and translation regulation factors (Buratti and Baralle, 2008; Colombrita et al., 2012;
Droppelmann et al., 2013a) Some also act as transcription factors, as well as regulators of premRNA splicing (Buratti and Baralle, 2008; Law et al., 2006; Leichter et al., 2011). Proteins,
such as TDP-43, FUS/TLS, TAF15 and RGNEF, have multiple roles in the regulation of RNA
metabolism and have been directly associated with ALS, including being observed within
pathological intracellular inclusions in both neuronal and non-neuronal cells in ALS
(Droppelmann et al., 2014; Keller et al., 2012). These RNA binding proteins and their functions
are further described below.
RNA bound with RNA binding proteins is found in discreet non-membrane bound
structures described as granules. Originally described as transport, stress or degradative granules,
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it is becoming clear that the distinction between granules is less clear and that RNA binding
proteins may be found across several different granule types (Buchan, 2014). Some granules
found within neurons are Cajal bodies, paraspeckles, transport granules, stress granules and Pbodies (degradative granules). Transport granules contain kinesin, and function to move RNA
throughout the cell utilizing kinesin’s transport capabilities along the cytoskeleton (Kanai et al.,
2004). Degradative granules are thought to be organelles in which RNA is de-capped and
degraded, usually involving exoribonuclease 1 (XRN1) or endonucleases (Luo et al., 2018).
Stress granules are discreet granules in which translation or degradation of the mRNA does not
occur, instead the RNA appears to be held quiescent, most commonly in cases of cellular stress,
until stress has ceased and the transcript is required again by the cell (Figure 1) (Buchan, 2014).
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Figure 1: Granules and ALS-related RNA binding proteins in RNA metabolism. Schematic detailing the localization of RNP

Figure 1: Granules and ALS-related RNA Binding proteins in RNA Metabolism. Schematic

granules in the metabolic pathway of RNA. Transport granules only occur in cells with axons.

detailing the localization of RNP granules in the metabolic pathway of RNA. Transport granules
only occurs in cells with axons.
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1.3

TDP-43

Until recently, the nature and structure of NCIs and what proteins or molecular species were
contained within remained a mystery. A major breakthrough occurred in 2006, when TDP-43
was found to be a major component of these aggregates in both frontotemporal dementia and
ALS (Arai et al., 2006; Cairns et al., 2007; Neumann et al., 2007). Originally observed to repress
HIV-1 transcription by binding to the HIV long terminal repeat (Ou et al., 1995), TDP-43 also
recognizes gene regulatory elements of the cystic fibrosis trans-membrane conductance regulator
(CFTR), where it influences exon 9 alternative splicing (Buratti et al., 2001). In addition, TDP43 plays a role in microRNA biogenesis, apoptosis, the cell cycle, as well as mRNA splicing,
processing and stability (Buratti and Baralle, 2008; Colombrita et al., 2012). TDP-43 has also
been found to be autoregulatory towards its own splicing (Budini and Buratti, 2011).
A schematic of TDP-43 structure can be seen in Figure 2. The protein contains a nuclear
localization signal (NLS), two RNA recognition motifs (RRM1 and RRM2), a nuclear export
signal (NES) and a C-terminus, intrinsically disordered, prion-like glycine rich domain (G-Rich)
(Figure 2). We now understand TDP-43 to be a ubiquitously expressed and highly conserved
protein in mammals (Ayala et al., 2005; Wang et al., 2004).
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Figure 1: The protein structure of TDP-43. 414 amino acids long, TDP-43 has been found to harbor over 400 mutations in ALS, a majority are
Figure
2: The protein structure of TDP-43. 414 amino acids long. NH2 denotes amino
found within the intrinsically disordered, glycine rich domain.

terminus. COOH denotes carboxy terminus.
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Recent evidence has linked TDP-43 to the stress response in cells. Normally a nuclear
protein with a small amount of expression in the cytosol, TDP-43 has been observed to relocalize to the cytoplasm in a reversible manner upon injury or under stress conditions.
Following sciatic axotomy in mice, immunohistochemistry showed TDP-43 to be cytosolic,
where it then returned to the nucleus upon recovery, signifying that TDP-43 cytosolic
sequestration is a normal response to stress (Moisse et al., 2009). In that same paper, TDP-43
was observed to co-localize with Staufen-1 and TIA-1 positive granules, suggesting TDP-43 may
be normally involved in the stress response of the cell. TDP-43 may also be involved in stress
granule formation. TIA-1 and G3BP, necessary components for stress granule formation, have
been shown to be regulated by TDP-43 (McDonald et al., 2011). This observation was later
strengthened when stress granule formation was reduced with the A382T mutation in TDP-43
(Orru et al., 2016). Through unknown mechanisms in ALS, TDP-43 appears to permanently
localize to the cytosol, unable to return to the nucleus.
TDP-43 has also been observed to directly bind with human NEFL mRNA at its 3’ UTR
binding site, implicating it in the previously mentioned reduced levels of NEFL mRNA in motor
neurons of ALS (Strong et al., 2007).
Several other RNA binding proteins have been observed to co-localize with TDP-43 in
ALS NCIs (Keller et al., 2012). How and whether these RNA binding proteins interact or modify
the toxicity of one another in ALS remains unknown. One protein that has yet to be investigated
that falls within the list of TDP-43 co-localizing RNA binding proteins is RGNEF.

1.4

RGNEF
RGNEF is a ubiquitously expressed RNA binding protein, with a dual role as a guanine

nucleotide exchange factor (Droppelmann et al., 2013a). Its structure is comprised of an Nterminal Leucine-rich domain, a zinc finger domain, a pleckstrin homology domain with a
nuclear localization signal imbedded within it, a RNA binding domain and a guanine exchange
factor domain (Figure 3). Its expression pattern is predominantly cytosolic in localization in
HEK293T cells, N2A cells, and human tissue. It acts as both a signal transduction protein
activating RhoA signaling pathways and as a stability factor of select mRNAs (Droppelmann et
al., 2013a; Volkening et al., 2010). The mouse homologue p190RhoGEF has been found to
interact with murine NEFL mRNA and allow for transcript stabilization (Canete-Soler et al.,
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2001). RGNEF was also been found to interact with human NEFL mRNA (Droppelmann et al.,
2013a; Volkening et al., 2010). However, opposite to its murine form, human RGNEF causes
the destabilization of NEFL mRNA (Droppelmann et al., 2013a). When overexpressed in
HEK293T cells, RGNEF decreases NFL protein expression suggesting that the interaction of
RGNEF with the NEFL mRNA is sufficient to alter NFL protein expression (Droppelmann et al.,
2013a). It has been determined that RGNEF interacts with NEFL mRNA in ALS tissues, while it
is does not appear to interact in control spinal cord lysates (Volkening et al., 2010). This
suggests that RGNEF may be a very important stability modulating factor of NEFL mRNA in
ALS.
Like other RNA binding proteins, RGNEF has been observed to form NCI’s in ALS
spinal motor neurons. These inclusions have also been observed to co-localize with TDP-43 and
FUS/TLS (Keller et al., 2012). Although rare, RGNEF has also been observed to harbor a
frameshift mutation in both familial and sporadic ALS cases(Droppelmann et al., 2013b; Ma et
al., 2014). This frameshift mutation is predicted to produce 2 different sized truncations of the
amino terminal region of RGNEF (Table 1).
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Figure 1: The
protein
structurestructure
of RGNEF. RGNEF
is approximately
1731is
amino
acids
long. NH
2 denotes amino-terminal and
Figure
3: The
protein
of RGNEF.
RGNEF
1731
amino
acids
long. NH2 denotes
COOH denotes carboxyl terminal.

amino terminus. COOH denotes carboxyl terminus.
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Recent work has shown that RGNEF can function as a pro-survival factor under osmotic
and oxidative stress conditions. When exposed to sodium arsenite (oxidative stress) and sorbitol
(osmotic stress), HEK293T cells transiently transfected with RGNEF showed significantly
improved survivorship. This effect was found to be abolished under osmotic, but not oxidative
stress conditions when the amino terminal region containing the Leucine-rich domain was
deleted (Cheung et al., 2017). What role L-Rich plays in the its protective function remains
unknown.
The localization of RGNEF under these stress conditions was also examined, revealing
that under both osmotic and oxidative stress, RGNEF localized with Staufen-1 positive granules
but not TIA-1 positive granules. What has yet to be investigated is whether RGNEF localizes
with TDP-43 under these stress conditions and whether RGNEF, or truncation constructs of it,
can protect against TDP-43 toxicity.

1.5

Leucine-rich domains
Leucine-rich repeats or Leucine-rich domains typically form solenoid protein structures

found in intracellular, extracellular, and membrane-bound proteins. These Leucine-rich
containing proteins are involved in signal matrix assembly, signal transduction, cell adhesion,
mammalian development, DNA repair, and RNA processing, hormone receptor interactions,
enzyme inhibition, cellular trafficking, cell polarization, regulation of gene expression, apoptotic
signaling, as well as playing a critical role in the morphology and dynamics of the cytoskeleton
(as reviewed in (Bella et al., 2008)). Often spanning 20-30 amino acids in length, Leucine-rich
domains are structurally characterized by a tandem external alpha helix and internal parallel beta
sheet repeat (Figure 4) (Kobe and Deisenhofer, 1993). There are currently 313 known human
genes that encode for Leucine-rich repeat proteins. Containing hydrophobic Leucine residues
with either a linear/open or circular/closed conformation, this domain has an 11-residue signature
sequence “LxxLxLxxN/CxL” (L = Leucine, x = any amino acid, N = asparagine) (Buchanan and
Gay, 1996; Kobe and Deisenhofer, 1995). It has been predicted that the presence of a Leucinerich, parallel, hydrophobic beta sheet is an ideal region for ligand binding and protein-protein
interactions. The concave shape created by this structure is predicted to increase the points of
protein-protein contact between the Leucine-rich domain and its target ligand.
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Figure 4. Examples of Quaternary structure of Leucine-rich repeat motifs (reproduced from
(Bella et al., 2008) with permission). (A) Crystal structure of ribonuclease inhibitor protein A1,
the first discovered crystal structure of Leucine-rich repeats. (B) Crystal structure showing a
dimerization of two Leucine-rich repeat variants. (C) crystal structure of Internalin A protein
binding to its ligand e-cadherin on the concave side of the leucine rich repeat motif. (D) Another
example of the Leucine-rich repeat binding to its ligand where a shorter repeat found on the
follicle stimulating hormone receptor binds to the follicle stimulating hormone on the concave
side.
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Several different sub-families of the Leucine-rich domain have been described, all
sharing the same signature sequence described above with distinct differences (Bella et al., 2008;
Kobe and Kajava, 2001).
Leucine-rich domains have previously been implicated in neurodegenerative diseases.
Mutations in the LRRN3 (Leucine-rich repeat neuronal 3) gene have been found in autism
spectrum disorder (Sousa et al., 2010), while Toll-like receptors, mediators involved in the
detection of pathogens in the immune response, contain Leucine rich repeats and have been
implicated in Multiple Sclerosis, stroke and Alzheimers Disease (as reviewed in (Okun et al.,
2009)).
In this thesis, “Leucine-rich domain” refers to the domain exclusively, while “L-Rich”
refers to the amino-terminal fragment of RGNEF used in this thesis that includes a Leucine-rich
domain. In silico predictions of L-Rich reveal it to have a linear or open solenoid structure
(Figure 5). Leucine-rich domains with this linear structure have a greater capacity to
accommodate imperfect complementarity in binding, suggesting that RGNEF may be able to
interact with macromolecules beyond its intended ligands or targets. When RGNEFΔL was
expressed under oxidative and osmotic stress conditions, HEK293T cells showed improved
survivorship under oxidative stress but not osmotic stress, whereas full length RGNEF showed
improvement in both (Cheung et al., 2017). This suggests that L-Rich may have a regulatory
purpose towards RGNEF’s role in the stress response to oxidative stress of the cell. However,
despite these preliminary investigations, how this domain ultimately functions in RGNEF and in
RNA metabolism remains unknown.
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Figure 5. In silico prediction of the structure of the Leucine-rich domain of RGNEF. The
model was created using I-Tasser (http://zhanglab.ccmb.med.umich.edu/I-TASSER) (116-118)
and manipulated using RasMol v2.7.5 software (Bernstein + Sons, Shirley New York).
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1.6

Drosophila melanogaster as a Model System

Drosophila have been a key model for investigating protein toxicity and genetic modification in
neurodegeneration. Drosophila have also been used extensively to investigate the roles of RNA
binding proteins in neurogenesis and neurological diseases (as reviewed in (Olesnicky and
Wright, 2018)). There is a high genetic overlap between Drosophila and humans that allows for
key insights into neurological diseases (Bilen and Bonini, 2005; Bonini, 2001; Driscoll and
Gerstbrein, 2003). To date, Drosophila have been used to investigate tauopathies (Heidary and
Fortini, 2001; Shulman and Feany, 2003; Wittmann et al., 2001), Huntington’s disease
(Kazantsev et al., 2002), Alzheimer’s and Parkinson’s disease (Feany and Bender, 2000; Shen et
al., 2017), polyglutamine diseases (Bonini, 1999; Jackson et al., 1998) and many other
neurodegenerative disorders. RNA mediated neurodegeneration and the stress response have also
been investigated (Arrigo, 1995; Jin et al., 2003; Orr, 2004). ALS and its related proteins and
genetic mutations have also been investigated through Drosophila models, exploring pathology
such as pro-inflammatory effects and glial abnormalities (Cantera and Technau, 1996; Nguyen et
al., 2001).
Given the short lifespan, longitudinal studies from early development to later adulthood
can be completed rapidly as compared to other model systems. On top of this, Drosophila
produce many progenies which allows for large scale genetic screens that have identified many
crucial genes within a variety of biological processes that share sequence and function with
mammals. Drosophila also contain a highly compact genome with only 4 chromosomes. This
model system can be given genes associated with human diseases through P-element mediated
transgenesis that can then be analyzed for downstream biological consequences. The functional
consequences of these transgenes can then be analyzed through various biochemical methods
unique to Drosophila. One system that is commonly used is called the GAL4-UAS system
(Figure 6) (Brand and Perrimon, 1993). In this system, the gene of interest is cloned into a
pUASt vector that is microinjected into the germline of a w- fly line which lacks the expression
of the protein necessary to produce a wildtype red eye colour. Progeny containing the transgene
reproduce a wildtype eye colour since the pTW-UAST vector contains the w+ gene. Upstream to
the transgene lies an upstream activation sequence (UAS) that will drive expression of the
transgene only in the presence of Gal4, a yeast transcription activator protein. A separate line,
known as a Gal4 driver line, contains Gal4 in the genome that will utilize the promotor of
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another protein in the desired tissue to drive its expression. This is known as enhancer trapping,
where an enhancer relating to a tissue specific gene is hijacked to drive instead the expression of
another gene, in this case Gal4. Following the crossing of these two lines together, expressed
Gal4 binds to the UAS resulting in expression of the transgene in desired tissue. This system is
extremely precise in its execution with there being several drivers to choose from; each with
unique, tissue specific expression. This system also allows the production of double transgenic
fly lines, where two proteins foreign to the fly can be analyzed for their collective effects.
Drosophila has been helpful in illuminating the underlying mechanisms behind TDP-43
toxicity. Common TDP-43 phenotypes observed to date are degeneration of the structure of the
eye, under-developed or shriveled wings, a severe decline in motor function and a reduced life
span (Feiguin et al., 2009; Hanson et al., 2010; Miguel et al., 2011). This effect takes place for
both wildtype and mutant TDP-43 isoforms. It is yet to be determined what effects L-Rich will
have on lifespan, motor function, and eye degeneration in the fly. It is equally unclear what
effect this domain will have on TDP-43 toxicity in a double transgenic fly model.
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Figure 6. The GAL4-UAS system. Schematic describing the mechanism of the GAL-UAS.
Gal4 fly lines (Driver) expressing the yeast transcription activator protein Gal4 in specific tissue,
are crossed with reporter lines (Reporter) containing a gene of interest (Transgene) downstream
to an upstream activation sequence (UAS). The Gal4 binds to the UAS, resulting in expression
of the gene or transgene. Expression only occurs where the tissue specific promoter is expressed.
Illustration modified from (Wimmer, 2003).
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1.7

Hypothesis, Objective and Significance

The effect of RGNEF in modifying TDP-43 toxicity has yet to be explored in Drosophila. How
L-Rich is important in this relation remains to be determined. Exploring how TDP-43 toxicity
changes in relation to these proteins will elucidate our understanding of how RGNEF relates to
TDP-43 and potentially other RNA binding proteins. Previous findings show that TDP-43 is
essential for development and that knockout of TDP-43 in mice is embryonic lethal (Gendron
and Petrucelli, 2011). Previously, it has been demonstrated that overexpression of either wildtype
or mutant forms of human TDP-43 in Drosophila is sufficient to induce neurotoxicity (Hanson et
al., 2010; Li et al., 2010; Ritson et al., 2010). It remains to be determined how L-Rich will play
into all of this. In vitro analysis suggests that it has no independent benefit but that it is essential
for full length RGNEF's protection against TDP-43. Cell viability work showing RGNEF
benefits have yet to explore the different constructs of RGNEF in relation to TDP-43. I
hypothesize that L-Rich is essential for full length RGNEF’s protective modification of TDP-43
toxicity.
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Chapter 2
2.1

In Vitro Methods

2.1.1 Cell lines and transfections
Human embryonic kidney cells (HEK293T cells, Dharmacon, Cat. #HCL4517) were maintained
in Dulbecco's modified Eagle's medium (DMEM; Life Technologies Inc., #11995-065)
supplemented with 10% of fetal bovine serum (FBS; Gibco, Life Technologies Inc.), 100 U/ml
penicillin/streptomycin (Life Technologies Inc., Burlington ON, #15140-122) and 5 g/ml of
plasmocin (Life Technologies Inc., #ant-mpt)). Cells were grown in a water-jacketed, 37°C, 5%
CO2 incubator (VWR, #10810-878).
Different constructs created in pcDNA3.1(+) vector (Thermo Fisher Scientific, #V79020) already available at the Strong laboratory were used for transient transfections in HEK293T.
RGNEF and RGNEFΔL contained a myc tag fusion protein on the C-terminus (pcDNA-RGNEFmyc and pcDNA-RGNEFL-myc, respectively), while the L-Rich contained a flag tag on the Nterminus (pcDNA- flag- L-Rich). All constructs were purified using the HiPure Plasmid
Midiprep kit (Invitrogen, #K21005) according to the manufacturer’s protocol.
Transfections were performed using Lipofectamine 2000 (Life Technologies, #11668019) and Opti-MEM Reduced Serum Media (Life Technologies, #31985-070) according to the
manufacturer's protocol. Cells were transfected at 70% confluency 48 hours post-seeding. For 6
well plate transfection, a lipofectamine/DNA mix was made with the ratio 2.5 μl for every 1 ug
of plasmid to be transfected. 2 ug of each plasmid DNA was combined with 250 μl of OptiMEM in a 1.5 ml Eppendorf tube and allowed to incubate for 5 minutes. The Lipofectamine
master mix with the appropriate ratio was made and allowed to incubate at the same time.
Immediately after, 250 μl of the master mix was added to each DNA mix for a total volume of
500 μl and allowed to incubate at room temperature for 20 minutes. The media was removed
from the cells and replaced with 1 ml of Opti-MEM per well during this time. The
Lipofectamine/DNA mixture was added to the 6 well plate and incubated at 37oC in 5% CO2 in
air, for 3.5 hours. Then, 500 μl of culture media were added to each well as well as 7.5 μl of
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200x Pen Strep, or 15 μl of 100x Pen Strep, after which cells were returned to the incubator and
allowed to recover overnight.
For 96 well plate transfection, the ratio between lipofectamine remained the same, with
100 ng of DNA loaded into each well and therefore 0.25 μl of lipofectamine as well. Following
incubation for 3 hours transfection solution was gently removed and replaced with 100 μl of
fresh media. Cell were allowed to equilibrate for 30 hours.
2.1.2 Protein Extraction
HEK293T cells grown in 6-well plates were lysed in cold lysis buffer (1x PBS pH 7.4, 1% Triton
X-100 and 1x complete protease inhibitor cocktail (Sigma-Aldrich # 11697498001)). For all
assays except the Cytotoxicity assay, protein was extracted 48 hours post transfection. For the
Cytotoxicity assay, protein was extracted in parallel from 6 well plates at 30 hours.
Cells were placed on ice and media were discarded. Cells were washed once with ice cold
1x PBS. 200 l of lysis buffer was then added to each well and cells lysed by pipetting up and
down 6-8 times before transfer to a cooled 1.5 ml Eppendorf tube. Samples were then sonicated
at an amplitude of 40 nm for 10 seconds for 2 cycles. Samples were then centrifuged for 10
minutes at 10,000 x g at 4°C. The supernatant was transferred to a new 1.5 ml Eppendorf tube
and protein quantification was determined using the DC protein assay kit (BIORAD, Reagent A
#500-0113, Reagent B #500-0114, Reagent S #500-0115), according to the manufacturer’s
protocol. Samples were labeled then stored at -20°C.
2.1.3 Western Blot
For protein expression confirmation from HEK293T cells and flies, 100 g of total protein for
each sample was denatured at 95°C for 1 minute and electrophoresed on 8%, 10% or 12.5%
SDS-PAGE polyacrylamide gels depending on the molecular weight of the protein being
examined. The separating gel was made of a lower buffer solution (1.5 M Tris-Base, 0.4% SDS,
pH 8.8), 29:1 acrylamide/bis, 1% ammonium persulfate, 0.0018% TEMED and distilled water.
The stacking gel was made up of an upper buffer solution (0.05 M Tris-Base, 0.4% SDS pH 6.8),
1 % ammonium persulfate, 29:1 12.5% acrylamide/bis, 0.002% TEMED and distilled water. The
gels were run at a constant 100 V in 1X running buffer solution (0.05 M Tris-Base, 0.2 M
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Glycine, 2 mM SDS) for 2 hours. Proteins were then transferred to nitrocellulose membranes
(BIORAD, #1620112), using a cooled wet transfer tank at 300 mA for 90 minutes in transfer
buffer solution (25 mM Tris-Base, 0.19 M Glycine, 20% MeOH). After transfer, membranes
were incubated in a 5% skim milk 1x blocking solution (0.05 M Tris Base, 0.1 M NaCl, 1%
Tween-20, pH 7.4) for 1 hour. Membranes were then incubated with primary antibodies (Table
1) in 5% milk 1x blocking solution for 90 minutes at room temperature, followed by a 10-minute
wash in 5% milk blocking solution, then secondary antibodies (Table 2) in 5% milk 1x blocking
solution for 60 minutes at room temperature. Membranes were washed 3 times for 15 minutes in
fresh 5% milk blocking solution, followed by a 5-minute wash in 1x PBS (pH 7.4) and incubated
with chemiluminescence reagents (Western Lightning Plus ECL, PerkinElmer,
#NEL104001EA). They were then visualized using a phospho-imager (BIORAD, Universal
Hood 3).
2.1.4 Immunofluorescence
22x22 mm coverslips were sterilized in 100% ethanol, allowed to dry and then washed in culture
medium and placed in a 6-well plate. Coverslips were then treated with 1 ml of 1x attachment
factor (Thermo Fisher Scientific #S006100) and set to dry for 45 minutes. Cells were seeded
onto the 6-well plate at 150,000 cells/ml and culture medium added to a total volume of 2 ml per
well. After 48 hours cells were transfected with 2 g of plasmid DNA, as described earlier. 24hours post-transfection, cells were exposed to either 70 μM Ethacrynic Acid (Sigma-Aldrich,
#SML1083-10MG) for 5 hours or 400mM Sorbitol (Aldrich, #240850-100G) for 4 hours.
Following stress, media was fully removed, and cells were gently washed once with 1x PBS (pH
7.4). Cells were then fixed in 1 ml of 4% paraformaldehyde in 1x PBS for 15 minutes at room
temperature. Following two washes with 1 ml of 1x PBS each, cells were then permeabilized
with 1 ml of 0.2% Triton X-100 in 1x PBS for 10 minutes at room temperature. Cells were then
washed with 1 ml of 1x PBS and incubated with 1 ml of 50 mM ammonium chloride in 1x PBS
for 30 minutes, then washed with 1 ml of 1x PBS and, finally, 1 ml of 8% BSA in 1x PBS
(blocking solution) was added to each well to block for 1 hour. Following blocking, coverslips
were removed from the 6-well plate and placed in a wet chamber containing 200 l droplets of
8% BSA solution with primary antibody (Table1). Coverslips were incubated with primary
antibodies for 1.5 hours at room temperature. Then, cells were washed once with blocking
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solution in the 6-well plate while the wet chamber was prepared for secondary antibody
incubation. Coverslips were incubated with 200 l droplets containing appropriate secondary
antibodies in the wet chamber for 1 hour in darkness (Table 2). Nuclei were then counterstained
with 1x DAPI for 5 minutes in darkness. Coverslips were then incubated in fresh 1x PBS twice
for 10 minutes in darkness where they were finally washed with distilled water and set to dry
face up in a covered dark chamber overnight. The following day, coverslips were mounted onto
labeled slides with fluorescence mounting media (Dako, #S3023) and allowed to dry in the same
dark chamber overnight. Slides were then visualized by confocal microscopy (Leica TCS SP8,
Leica Microsystems CMS GmbH) with LAS X software (Leica Microsystems CMS GmbH).
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Table 2: Primary Antibodies used in this study
Antigen

Supplier

Catalogue #

Use

Dilution

Alpha-Tubulin

Sigma-Aldrich

T-5168

Western Blot

1:3000

Flag

Sigma-Aldrich

F1804-50UG

Western Blot

1:5000

Immunofluorescence

1:500

Western Blot

1:2500

Immunofluorescence

1:250

Western Blot

1:2500

Immunoprecipitation

1 g/ml

Immunofluorescence

1:250

Western Blot

1:1000

Immunofluorescence

1:100

11570-AP

Western Blot

1:500

ab9485

Western Blot

1:20000

Myc

TDP-43

Staufen-1

FUS

Cedarlane

Proteintech

Millipore

Proteintech

GAPDH

CLX229AP

60019-2-1g

ab5781

Rabbit IgG

Santa Cruz

L2414

Immunoprecipitation

1 g/ml

TIA-1

Santa Cruz

sc-1751

Immunofluorescence

1:100

Use

Dilution

Table 3: Secondary Antibodies used in this study
Antigen

Supplier

Catalogue #

(HRP/ Fluorescent)
α - Mouse

BioRad

170-6516

Western Blot (HRP)

1:3000

α - Rabbit

Invitrogen

65-6120

Western Blot (HRP)

1:5000

Donkey α –

Invitrogen

A21202

Immunofluorescence

1:1000

Mouse

(Fluorescent)

(Alexa 488)
Donkey α –

Invitrogen

A31572

Rabbit

Immunofluorescence

1:1000

(Fluorescent)

(Alexa 555)
DAPI

Sigma-Aldrich

D9542

Immunofluorescence
(Fluorescent)

1:1000
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2.1.6 Cytotoxicity Assay
HEK293T cells were seeded at 10,000 cells/ml per well in a white bottom 96-well plate. After 24
hours, culture media was removed and cells were transfected as described in the protocol above.
In this protocol 100 ng of DNA was transfected per well, and the ratio of DNA to lipofectmine
was 1 ng:2.5 l. Cells were incubated for 3 hours with the transfection mix, at which time all
transfection media was removed and replaced with 100 l of culture media. Cells were allowed
to rest for 30 hours. 10 ml of culture medium alone, or containing either 400 mM of Sorbitol or
70 M Ethacrynic acid were prepared. 100 l of culture media alone was added to the first plate,
and 100 l of culture medium containing either ethacrynic acid or sorbitol were added to the
other plate. For sorbitol, cells were then incubated for 4 hours while cells treated with sodium
arsenite were then incubated for 1 hour. Quantification of the number of dead cells was
performed using Cytotox-Glo cytotoxicity assay (Promega, #G9291) following manufacturer’s
instructions. Briefly, after culture media was removed, 50 l of CytoTox-Glo cytotoxicity assay
reagent was added to each well. The plate was gently agitated using an orbital shaker then
incubated at room temperature for 15 minutes in darkness. Luminescence from the experimental
condition was measured using a luminometer (Turner Biosystems #998-9102). Afterwards, 50 l
of lysis reagent was added to each well. The plate was mixed via orbital shaker and incubated at
room temperature for 15 minutes in darkness. Luminescence following cell lysis was measured
using the luminometer. Luminescence from the experimental condition was subtracted from the
total cell lysis luminescence.
2.1.7 Immunoprecipitation
50 l of recombinant Protein G-Sepharose 4B conjugated beads (Invitrogen #10-1241) were
added to 1 ml of NP40 substitute lysis buffer (IGEPAL-CA630, Sigma-Aldrich, #18896-100ML)
in 1x TBS solution (1% NP40 substitute, 1x protease inhibitor cocktail in 1x TBS). 1 g of IP
antibody was added to the solution and agitated at 4oC for 30 mins. Following incubation, the
NP40 buffer was removed and beads were blocked with 8% BSA dissolved in 1x TBS solution
for 1 hour and 30 minutes. Beads were then incubated with 500 g of protein lysate and agitated
overnight at 4°C. The following day, beads were washed first in 0.5% TritonX-100 with 1%
NP40 buffer in 1x TBS, then 1% NP40 Buffer in 1x TBS, and then 1x TBS each with a 12,000 x
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g centrifugation at 4°C for 2 minutes between each wash. After the final wash, the supernatant
was removed and 30 l of 1x TBS were added with 15 l of loading buffer (0.08 M Tris-Base,
10% SDS, bromophenol blue, 50% glycerol, 2.5% beta-mercaptoethanol pH 7.4). Samples were
heated at 65°C for 10 minutes then centrifuged for 2 minutes at 12,000 x g at room temperature.
2.1.8 In vitro Statistical Analysis
The statistical analysis was performed with Prism 6 (GraphPad Software, Inc., CA, USA) using
Student's t-test when comparing two groups or one-way ANOVA with Student-Newman-Keuls
post-hoc test when comparing more than two groups. Significance is represented using asterisks;
**** denotes p<0.0001, *** denotes p<0.001, ** denotes p<0.01, * denotes p<0.05.

2.2

In Vivo Methods

2.2.1 Fly Crosses and Stocks
For the generation of transgenic flies, the coding regions of TDP-43wt and flag-LeuR were
cloned in the pTW-UASt vector (Drosophila Genomics Resource center). The UAS-TDP-43wt
and UAS-LeuR transgenic lines were generated by random germline insertion into w1118 flies
lacking protein expression for wildtype red eyes (BestGene) (Droppelmann et al., unpublished
results). Upon insertion, if the transgenic vector was successfully taken up in the genome, white+,
found within the vector, would re-establish the wildtype red eye pigment. GMR-Gal4, D42Gal4, and elav-Gal4 driver fly lines were obtained from the Bloomington Drosophila Stock
Center (Indiana University, Bloomington, Indiana, USA.) (Table 3). Stocks and crosses were
cultured according to standard procedures and on standard fly food (Water, Yeast, Soy fluor,
Yellow Cornmeal, Agar, Light Corn Syrup, Propionic acid) (Bloomington Drosophila Stock
Center). Food was produced and provided by Dr. Kramer’s lab. Crosses were raised on 25°C and
70% humidity at a 12 hour day/night cycle.
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Table 4: Enhancer Trap Gal4 Drivers used in this study
Name

Stock

Symbol

Chr.

Expression

Genotype

P{GAL4-

2

Eye*

w[*] ; P{w[+mC]=GAL4-

#
GMR

1104

ninaE.GMR}12
D42

8816

P{GawB}D42

ninaE.GMR}12
3

Motor

w[*]; P{w[+mW.hs]=GawB}D42

Neuron
elav

458

P{GawB}elav[C155]

1

Pan-

P{w[+mW.hs]=GawB}elav[C155]

Neuronal**

* = Provides strong expression in all cells behind the morphogenetic furrow.
**= Begins expression at stage 12 of embryonic development.
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Table 5: Genotype of transgenic flies analyzed in this thesis. collected prior to crossing and
following crossing with respective Gal4 Drivers.
Transgenic flies
Drivers
No
Cross

Control

L-Rich

TDP-43

L-Rich + TDP-43

w-

(w-; UAS-flag-L-Rich,

(w-; +/+;UAS-

(w-/+;UAS-flag-L-Rich;

(Parent line)

w+/CyO; +/+)

hTDP-43,

UAS-hTDP-43wt)

Or

w+/TM3, Sb)

(w-; UAS-flag-L-Rich,

Or

w+; +/+)

(w-; +/+;UAShTDP-43, w+)

GMR

(+/+;

(+/w-; UAS-flag-L-

(+/w-; +/GMR;

(+/+; UAS-flag-L-

+/GMR;

Rich/GMR; +/+)

UAS-hTDP-

Rich/GMR; UAS-hTDP-

43wt/+)

43wt/+)

+/+)

Or
(+/w-; UAS-flag-LRich/GMR; UAS-hTDP43wt/+)
D42

(+/+; +/+;

(+/w-; UAS-flag-L-

(+/w-; +/+;UAS-

(+/+;UAS-flag-L-Rich/+;

+/D42)

Rich/+; +/D42)

hTDP-

UAS-hTDP-43wt/D42)

43wt/D42)

or
(+/w-; UAS-flag-LRich/+; UAS-hTDP43wt/D42)

Elav

(+/Elav;

(Elav, +/ w-; UAS-

(Elav, +/ w-;

(Elav, +/+; UAS-flag-L-

+/+; +/+)

flag-L-Rich/+; +/+)

+/+;UAS-hTDP-

Rich/+; UAS-hTDP-

43wt/+)

43wt/+)
Or
(Elav, +/ w-; UAS-flag-LRich/+; UAS-hTDP43wt/+)
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The genotypes for single transgenic flies were {w-; UAS-flag-L-Rich, w+/CyO; +/+} or
{w-; UAS-flag-L-Rich, w+; +/+} and {w-; +/+; UAS– hTDP-43wt/ TM3, Sb} or {w-; +/+; UAS–
hTDP-43wt}. CyO is a dominant 2nd chromosome balancer that is paired with a curly wing
mutation (Cy) and Sb is the symbol for a dominant stubbled hair mutation that is paired with the
TM3 3rd chromosome balancer. A total of 9 stable lines with different insertions of each
transgene of interest were created using P-element mediated transformation (Figure 7) (Rubin
and Spradling, 1982). Random insertion may be lethal or may produce a phenotypic effect
regardless of transgenic protein expression. Two lines were chosen out of the 9 from each
transgenic insertion to control for this effect and to compare relative expression effects. Two
lines of L-Rich transgenic flies (L2 and L4 respectively) which contain the gene locus on the
second chromosome, and two TDP-43 transgenic fly lines, containing the gene on the 3rd
chromosome were chosen (T6 and T9 respectively). Single transgenic flies homozygous for the
transgene were used in the generation of the double transgenic fly line as well as in crosses with
Gal4 drivers. Having the genes on separate chromosomes allowed for homozygosity of both
genes and the removal of all balancing markers when generating the double transgenic fly line
({+/w-; UAS-flag-L-Rich; UAS-hTDP-43wt; +/+}). The final genotypes of the progeny that were
analyzed along with controls were as follows in Table 5. Control crosses between Gal4 drivers
with the parental line used to produce the transgenic flies was done to account for any
phenotypic effect inherent to either the Gal4 driver or the parental line. Non-expressing
transgenic fly lines were also included as control groups to account for any phenotypic effect
caused by the insertion site of the transgene.
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Figure 7. Fly lines and their chromosomal insertions. Visual representation of the 9 lines
made for each protein and their chromosomal insertions. The lines highlighted in red were
chosen for analyses due to non-lethality and having produced transgenic expression, as
investigated by D. Droppelmann. TDP-43 line 6 and 9 are inserted on chromosome 3 L-Rich line
2 and 4 are located on chromosome 2. Lines were generated and contributed at beginning of
thesis from the Bloomington Stock center (image provided by Cristian Droppelmann with
permission).
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2.2.2 Balancing of Single Transgenic Fly lines and Generation of Double Transgenic fly line
Homozygous single transgenic fly lines with wildtype phenotype were crossed with a whole
chromosome, double balancer fly line with the genotype {w[*]; Kr[If-1]/CyO; Ki[1]/TM3,
Sb[1]}. This balancer line is modified from the #7198 stock found at Bloomington Drosophila
stock center. Kr is the symbol for crumpled eye mutation, CyO is a classical balancer that is
associated with a Cy allele that generates a curly wing mutation. Ki is the symbol for a hair
mutation where there is “kink” or bend in the hair follicle and lastly Sb is the symbol for a
stubbed or short hair mutation. Flies were balanced to allow the crossing between single
transgenic fly lines to create a double transgenic line that would be selected for a wild type
phenotype indicating homozygosity for L-Rich on the second chromosome and TDP-43 on the
3rd chromosome. Balanced L-Rich transgenic flies would contain a kinked, stubble hair
phenotype while TDP-43 balanced flies would contain a crumpled eye, curly winged phenotype.
Following additional crosses, progeny were selected for that were wildtype for all markers,
indicating the classical balancers were no longer present. The schematic below shows the 2nd and
3rd chromosome that was used for balancing the L-Rich transgenic fly line that would then be
crossed with TDP-43 transgenic flies to produce a double transgenic fly line with wildtype
phenotype and no balancers remaining. (Figure 8). The balancing of TDP-43 was completed by
Dr. Droppelmann
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Figure 8. Example of balancing scheme where L-Rich, balanced transgenic flies were
generated. The final product of the scheme would produce a transgenic fly homozygous for the
transgene of interest on the second chromosome and heterozygous for balancing markers on the
opposing chromosome to be identified during the cross with the balanced TDP-43 transgenic fly
lines that were balanced and provided by Cristian Droppelmann.
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Final progeny of the balanced lines for L-Rich and TDP-43 were crossed to generate the
double transgenic line. The offspring that had no phenotypic markers present were chosen
Representing homozygosity for both genes on chromosome 2 and 3 {+/+;LeuR;TDP-43}. These
flies were then run through analysis alone or crossed to drivers that drove tissue specific
expression of the transgene. For genomic analysis and protein and RNA expression, whole flies
were anaesthetized in a 1.5 ml microcentrifuge tube placed on ice. If not used immediately, flies
were retrieved after storing at -80°C and placed in a fresh tube.
2.2.3 Protein Extraction-Flies
Whole flies were homogenized in drosophila lysis buffer (20 mM HEPES pH7.5; 100 mM KCl;
10 mM EDTA; 1 mM DTT; 1% Triton X-100; 5% glycerol). The whole fly protein lysate was
sonicated at 60nm amplitude for 2 rounds of 10 seconds each, followed by a 30s centrifugation at
10,000 x g for a total of 3 repeats. A final 10,000 x g 10 min spin was used to pellet debris and
the supernatant was retained, quantified using the DC protein assay according to manufacturer’s
protocol. Samples were stored at -20°C until Western blots were performed (as described above).
2.2.4 RNA Extraction-Flies
10 flies were suspended in 1 ml of Trizol reagent (Ambion, Life Technologies, # 155960296)
and homogenized using a disposable plastic pestle. Homogenates were incubated at room
temperature for 5 minutes then centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant
was transferred to a new 1.5 ml tube and 200 µl of chloroform was added. Tubes were then
shaken vigorously by hand and incubated for 3 minutes at room temperature. Tubes were then
centrifuged at 10,000 x g for 15 minutes at 4°C. The upper aqueous phase was transferred to a
new tube where it was incubated with 500 µl of isopropanol for 10 minutes. The tubes were then
centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant was removed, and the pellets
were washed with 1 ml of 75% ethanol. The tube was then centrifuged at 7,500 x g for 5 minutes
at 4°C. The supernatant was removed, and pellets were allowed to dry for 10 minutes, then
resuspended in 100 µl of RNase free water and quantified using Nanodrop software (Nanodrop
1000, Thermo Scientific).
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2.2.5 DNA Extraction-Flies
20 Flies were homogenized in 200 µl of Buffer A (100 mM Tris-Cl (pH 7.5), 100 mM EDTA,
100 mM NaCl, 0.5% SDS) using a disposable tissue grinder. An additional 200 µl of Buffer A
was added to a total volume of 400 ul and flies were furthered grinded for 2 minutes. Samples
were incubated at 65°C for 30 minutes with 800 µl of Buffer B (5M potassium acetate, 6M
lithium chloride) added afterwards. Samples then incubated on ice for 2 hours. Following this,
samples were centrifuged at 12,000 x g for 15 minutes at room temperature. In a new
microcentrifuge tube, 850 µl of the supernatant from the previous tube was added. If there was
any precipitate present on the surface of the supernatant, the second tube was centrifugated at
12,000 x g for 15 more minutes with the supernatant from that tube being transferred to a fresh
tube. 510 µl of isopropanol was added to each sample and mixed well by inverting the tubes
several times. Samples were then centrifuged at 12,000 x g for 15 minutes at room temperature.
The supernatant was discarded, the pellet washed with 70% ethanol and then centrifuged at
12,000 x g for 5 minutes at room temperature. The 70% ethanol was removed, and pellets airdried for 10 minutes. Finally, pellets were resuspended in 150 µl of TE buffer (Invitrogen,
#12090015) and quantified via Nanodrop 1000 spectrophotometer. Samples were then stored at 20°C.
2.2.6 Agarose Gel Protocol
UltraPure Agarose (#16500-500) was added to 1x TAE buffer to a ratio of 1 g: 100 ml of buffer,
producing a 1% agarose gel solution. The solution was mixed and warmed in a microwave until
homogeneous. The agarose solution was mixed under cold water until it was cooled to
approximately room temperature. RedSafe (INtRON Biotechnologies, #21141) was added to the
solution at a ratio of 5 μl:100 ml. The gel solution was then poured into an agarose gel chamber
with a loading comb placed within, where it was left to polymerize at room temperature. Once
complete, the gel was transferred into a BIO RAD Mini Sub cell chamber (#1704466) and
submerged in fresh 1X TAE buffer. Sample were loaded with 5X Orange G loading buffer. 10µl
of GeneRuler 1 kb Plus DNA ladder (Thermofisher, #SM1331) was loaded in the first lane. Gels
were run at 100 volts for 40 minutes. The gel was then observed under UV light using a
phospho-imager.
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2.2.7 RT-PCR
2 ug of total RNA from extractions was reverse transcribed using the superscript II reverse
transcriptase system (Life Technologies). 2ug of total RNA was combined with 10x DNase
Buffer and 1U/ul of DNase I, topped to a total volume of 20ul using UltraPure RNase free water
(Invitrogen, #10977-015) in a microcentrifuge tube. Samples were then incubated at 25°C for 15
minutes. Afterwards, 2 ul of 25 mM EDTA was added and tubes then incubated at 65°C for 10
minutes. Randoms primers (3 ug/ul) were added and the samples were then heated to 70°C for 5
minutes then quickly put on ice. Afterwards, 8 ul of 5x RT Buffer, 1 ul of 25mM dNTPs, 1 ul of
RNase OUT, 0.5ul of 0.1 M DTT and 5.5 ul of UltraPure RNase free water was added to all
tubes. Lastly 1 ul of Superscript II RT was added and gently mixed in via pipetting, where then
tubes incubated at 42°C for 90 minutes. This was followed by 70°C for 15 minutes and finally
4°C, where tubes were held until ready to start PCR or were stored at -20°C. One sample served
as the negative RT control where RNA was used from non-expressing transgenic flies. Another
sample served as a second negative RT control where water was used instead of RNA to check
for contamination of the RT material with the template.
PCR reactions were set up using the Platinum Taq DNA polymerase (Life Technologies)
using manufacturer’s protocols and oligo primers. Briefly, 2.5 µl of 10x PCR Buffer, 1.25 µl of
50 mM MgCl2, 2.5 µl of 2.5 mM dNTP mix, 0.6 µl of 10 mM forward primer and 0.6 µl of 10
mM reverse primer, 2.5 µl of cDNA from the RT reaction, and 0.4 µl of Platinum Taq DNA
polymerase were mixed and the volume adjusted to 25 µl with RNAse/DNAse free deionized
water. In a thermocycler, samples were incubated to 94°C for 3 minutes to denature, 30 cycles of
the following temperatures with specific lengths of time: 94°C for 30 seconds, 62°C for 30
seconds, then 72°C for 30 seconds. Once the cycles were complete, the samples were run
through 72°C for 5 minutes and then held at 4°C until the electrophoresis was performed.
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Table 6: Primers used in PCR reactions to detect Genomic presence and RNA expression of LRich and human TDP-43 in fly homogenates.
Name

Forward or

DNA sequence (5’ to 3’)

Reverse
Primers
L-Rich

TDP-43

Forward

CAACATGGCTTGCAGGCTGGC

Reverse

CGGGAGAAGCTTGGGGACCA

Forward

GGACTTGATCATTAAAGGAATCAGCGTTC

Reverse

CTGCCCGACCCTGCATTGGATG
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2.2.8 Negative Geotaxis Assay (Climbing Assay)
F1 male progeny of transgenic flies (+/+; UAS-flag-L-Rich, UAS-hTDP-43wt;+/+, UAS-flag-LRich;hTDP-43wt) crossed with elav-gal4 and D42-gal4 driver fly lines were collected. The
following day, flies were transferred to a graduated cylinder divided into 4 vertical quadrants
sealed with parafilm. Flies were tapped to the bottom of the cylinder and the number of flies
present in each quadrant was recorded at 10s and 20s. Measurements were repeated a total of 4
times every 5 days for 30 days. Control flies were non-expressing transgenic fly lines (UAS-flagL-Rich;+/+, +/+;UAS-hTDP-43wt, UAS-flag-L-Rich;UAS-hTDP-43wt). Climbing index was
calculated using the formula:
Climbing Index= ((Quadrant*1) + (Quadrant2*2) + (Quadrant3*3) + (Quadrant4*4))/Total
number of flies
2.2.9 Lifespan assay
F1 male progeny of transgenic flies (+/+; UAS-flag-L-Rich, UAS-hTDP-43wt;+/+, UAS-flag-LRich;UAS-hTDP-43wt) crossed with elav-gal4 and D42-gal4 driver fly lines as well as driver
lines alone (w[*]; P{w[+mW.hs]=GawB}D42, P{w[+mW.hs]=GawB}elav[C155]) and nonexpressing transgenic lines (+/+; UAS-flag-L-Rich, UAS-hTDP-43wt;+/+, UAS-flag-LRich;hTDP-43wt) were collected. Flies were raised in an incubator set to 25°C at 70% humidity
with controlled day/night cycles in vials. The number of dead and live flies were counted every 5
days until no live flies remained. The data was analyzed using Kaplan–Meier estimator.
2.2.10 Eye Characterization
Single transgenic fly lines (L-Rich-2, L-Rich-4, TDP-43-6, TDP-43-9) and double transgenic fly
lines (L-Rich-2;TDP-43-6, L-Rich-2;TDP-43-9) were crossed with the GMR-gal4 driver line for
a total of 3 unique crosses. 5 male progeny with the genotype +/+; UAS-flag-L-Rich, UAS-hTDP43wt;+/+, or UAS-flag-L-Rich;UAS-hTDP-43wt were collected. The GMR-gal4 driver line (w[*]
; P{w[+mC]=GAL4-ninaE.GMR}12) crossed with the fly line (w1118) that was used by BestGene
to produce the transgenic fly lines, acted as control. Flies were on a 7-day schedule anaesthetized
with CO2 and placed in a petri dish sealed with parafilm. Flies were then photographed using a
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Nikon light microscope (NIKON SMZ800N, #C-FLED2) and returned to their vials once per
week for up to 7 weeks or until death.
2.2.11 Statistical Analysis
Kaplan-Meier estimate analysis was used to compare variance in lifespan curves. One-way
ANOVA with multiple comparisons tests were run for climbing assay comparisons.
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Chapter 3
3.1

In vitro Results

3.1.1 Cytotoxicity assay
Seeking to elucidate whether L-Rich is critical for the pro-survival role of RGNEF under
stress conditions, a cytotoxicity assay was performed on HEK293T cells transfected with full
length RGNEF, RGNEFΔL, L-Rich or the empty vector alone as negative control (pcDNA).
The Cell-Titer Glo Cytotoxicity Kit, which is a live-dead assay that allows for the
measure of cytotoxicity via luminescence, was used. The more live cells there are, the greater the
luminescence detected. 36 hours post-transfection, cells were either unstressed (control) or
subjected to either osmotic stress or oxidative stress. The concentrations for the stressors
(oxidative stress - ethacrynic acid 70 μM; osmotic stress – sorbitol 400 mM) were chosen based
on our previous experience and those found in the literature that reliably produce stress granules
(Cheung et al., 2017; Iguchi et al., 2012). Figure 9 shows the transfection efficiency of each
construct into HEK293T cells, including representative images. There was no significant
difference between the transfection efficiency of each construct (RGNEF – RGNEFΔL
p=0.8141; RGNEF – L-Rich p=0.1988; RGNEFΔL – L-Rich p=0.4193).
Figure 10A shows visual representations of the different constructs of RGNEF used in
the cytotoxicity assay. Also shown is a Western blot demonstrating protein expression of these
constructs alongside the pcDNA empty vector control. In the absence of either osmotic or
oxidative stress (Figure 10B), L-Rich and RGNEFΔL significantly increased cell survivoral
(p=0.007, p=0.0289, respectively), as did full-length RGNEF (p=0.0223) compared to pcDNA
control. When exposed to an osmotic stressor (400 mM sorbitol, Figure 10C), all groups showed
a significant reduction in luminescence compared to the non-stressed control (pcDNA-no stress)
(p=<0.0001). Compared to the stressed control group (pcDNA), RGNEF and RGNEFΔL showed
a significant increase in cell viability (p=0.0145 and p=<0.0001, respectively). L-Rich alone did
not confer increased viability compared to control. When including an oxidative stressor (70 μM
ethacrynic acid, Figure 10D), only the full-length transcript (RGNEF) significantly increased cell
viability (p=0.0145),
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Figure 9. Transfection efficiency of RGNEF constructs in HEK293T cells. A Representative
immunocytochemistry images of the RGNEF constructs transfected into HEK293T cells used to
count transfection efficiency. The constructs are: RGNEF-full length (RGNEF), RGNEF lacking
the leucine-rich domain (RGNEFΔL) and the leucine rich domain alone (L-Rich). A
representative image of nuclear staining is shown above (DAPI), as well as detection of either
myc-tagged RGNEF, myc-tagged RGNEFΔL or flag-tagged L-Rich. Scale bar = 10 μm. B Graph
showing transfection efficiency of each construct. Percentage derived from the number of cells
with expression divided by total cells visible in the image multiplied by 100 with at least 1000
cells were counted for each construct. ns = not significant. Scale bar = 20 μm.
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Figure 10. L-Rich region of RGNEF critical for oxidative stress but not osmotic stress. A
Schematic showing the 3 constructs of RGNEF used in the assay and the protein levels after
transfection in HEK293T. B, C and D Graphs shows data from Cytotoxicity live/dead assay
measuring luminescence through the Cyto-Tox Glo assay Kit. Experiments were performed in
HEK293T cells transiently transfected with RGNEF constructs. Cells were analyzed without
stress (B) and after exposed to osmotic (400 mM sorbitol for 4 hours) (C) and oxidative (70M
of ethacrynic acid for 5 hours) (D) stress conditions. Relative luminescence was calculated by
subtracting luminescence prior to lysis to the luminescence following cell lysis. * = p <0.05; **
= p<0.01; **** = p<0.0001. Data presented as mean ± standard error.
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3.1.2 Immunofluorescence
Seeking to determine the subcellular localization of the RGNEF constructs, HEK293T
cells were transfected with RGNEF, RGNEFΔL, or L-Rich and analyzed through
immunofluorescence to study colocalization with TDP-43. Prior to fixation, cells were left
unstressed, exposed to either osmotic (400 mM sorbitol), or oxidative (70 M ethacrynic acid)
stress. The pcDNA empty vector acted as transfection control (Figures 11-22).
In the absence of stress, cells transfected with only the pcDNA vector showed a
predominantly nuclear TDP-43 localization with minimal cytosolic granule formation (Figure
11). This observation persisted after transfection of all constructs of RGNEF under non-stress
conditions (Figure 12-14). This pattern of nuclear predominant TDP-43 localization in the
absence of cell stress or injury is consistent with reported literature (Ayala et al., 2008).
RGNEF localized predominantly to the cytoplasm (Figure 12). A similar pattern was
observed with RGNEFΔL (Figure 13). L-Rich showed a different pattern of distribution with
expression observed in the cytoplasm and the nucleus in some cells but not all. Some cells
showed expression predominantly in the cytoplasm while others showed the formation of L-Rich
immunoreactive granules (Figure 14).
Under osmotic stress conditions, pcDNA transfected control cells showed redistribution
of TDP-43 to the cytoplasm and the formation of cytosolic TDP-43 immunoreactive granules in
the cytoplasm (Figure 15). This pattern was also observed for all RGNEF constructs (Figures 1618). Full-length RGNEF formed granules, some of which co-localized with TDP-43 granules
(Figure 16, arrows in magnified inset box merge). RGNEFΔL formed granules, but these
granules rarely and minimally co-localized with TDP-43 granules (Figure 17). In contrast, LRich not only formed granules but also appeared to co-localize with TDP-43 immunoreactive
granules to a greater degree (Figure 18). It is important to note that despite the increase in colocalization, there are still L-Rich immunoreactive granules that did not appear to co-localize
with TDP-43 (Figure 18).
Under oxidative stress conditions, pcDNA transfected cells show redistribution of TDP43 to the cytoplasm with TDP-43 granule formation (Figure 19). Cells transfected with RGNEF
showed a change in morphology, where the cell appeared to form protruding structures
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uncommon to HEK293T cells. RGNEF did not form granules in response to oxidative stress and
maintained a more diffuse cytosolic staining pattern (Figure 20). TDP-43 however formed
granules and showed redistribution to the cytoplasm as expected under a stress condition. In cells
that highly expressed RGNEF, as indicated by a more intense immunofluorescence, the overall
expression of TDP-43 appeared to be lower compared to those cells expressing less or no
RGNEF. RGNEFΔL showed a similar predominantly cytosolic localization to that observed for
full length RGNEF (Figure 21) and no co-localization with TDP-43 immunoreactive granules. In
cells transfected with L-Rich, the localization was both cytoplasmic and nuclear with the
appearance of granules in or around the nucleus (Figure 22, white arrows). There was no colocalization with TDP-43 immunoreactive granules.
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Figure 11. TDP-43 localization is predominantly nuclear in the absence of exogenous stress.
Immunofluorescence showing localization of endogenous TDP-43 (red) with DAPI labeling of
nuclei (blue) and myc antibody (green) in HEK293T cells. Merge of fluorescence shown in
bottom right image. Scale bar = 10 m.
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Figure 12. RGNEF expresses mainly in the cytoplasm in the absence of exogenous stress.
Immunofluorescence showing localization of transfected myc-tagged RGNEF (green),
endogenous TDP-43 (red) and DAPI labeling of nuclei (blue) in HEK293T cells. Merge of
fluorescence shown in bottom right image. Scale bar = 10 m.

50

Figure 13. RGNEFΔL localizes mainly in the cytoplasm in the absence of exogenous stress.
Immunofluorescence showing localization of transfected myc-tagged RGNEFΔL (green),
endogenous TDP-43 (red) and DAPI labeling of nuclei (blue) in HEK293T cells. Merge of
fluorescence shown in bottom right image. Scale bar = 10 m.
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Figure 14. L-Rich localizes predominantly to the cytoplasm but also in the nucleus in the
absence of exogenous stress. Immunofluorescence showing localization of flag-tagged L-Rich
(green), endogenous TDP-43 (red) and DAPI labeling of nuclei (blue) in HEK293T cells. Merge
of fluorescence shown in bottom right image. Scale bar = 10 m.
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Figure 15. TDP-43 redistributes to the cytoplasm and forms granules following osmotic
stress. Immunofluorescence showing localization of endogenous TDP-43 (red) with DAPI
labeling of nuclei (blue) and myc antibody (green) in HEK293T cells exposed to 400 mM of
sorbitol for 4 hours. Merge of fluorescence shown in bottom right image. Scale bar = 10 m.
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Figure 16. RGNEF appears to co-localizes with TDP-43 granules following osmotic stress.
Immunofluorescence showing localization of transfected myc-tagged RGNEF (green),
endogenous TDP-43 (red) and DAPI labeling of nuclei (blue) in HEK293T cells following
exposure to 400 mM of sorbitol for 4 hours. Merge of fluorescence shown in bottom right image.
Lower panel is magnification of inset box. Arrows denote granules where co-localization is
observed. Scale bar = 10 m in both images.
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Figure 17. RGNEFΔL shows infrequent co-localization with TDP-43 granules following
osmotic stress. Immunofluorescence showing localization of transfected myc-tagged RGNEFΔL
(green), endogenous TDP-43 (red) and DAPI labeling of nuclei (blue) in HEK293T cells
following exposure to 400 mM of sorbitol for 4 hours. Merge of fluorescence shown in bottom
right image. Lower panel is magnification of inset box. Arrows denote granules. Scale bar = 10
m in both images.
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Figure 18. L-Rich co-localizes with endogenous TDP-43 granules following osmotic stress.
Immunofluorescence showing localization of flag-tagged L-Rich (green), endogenous TDP-43
(red) and DAPI labeling of nuclei (blue) in HEK293T cells following exposure to 400 mM of
sorbitol for 4 hours. Merge of fluorescence shown in bottom right image. Lower panel is
magnification of inset box. Arrows denote granules where co-localization is observed. Scale bar
= 10 m in both images.
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Figure 19. TDP-43 redistributes to the cytoplasm and forms granules following oxidative
stress with ethacrynic acid. Immunofluorescence showing localization of endogenous TDP-43
(red) with DAPI labeling of nuclei (blue) and myc antibody (green) in HEK293T cells exposed
to 70 M of ethacrynic acid for 5 hours. Merge of fluorescence shown in bottom right image.
Scale bar = 10 m.

57

Figure 20. RGNEF did not form granules and did not appear to co-localize with TDP-43
immunoreactive granules following oxidative stress with ethacrynic acid.
Immunofluorescence showing localization of transfected myc-tagged RGNEF (green),
endogenous TDP-43 (red) and DAPI labeling of nuclei (blue) in HEK293T cells following
exposure to 70 M of ethacrynic acid for 5 hours. Note the change in cell morphology. Merge of
fluorescence shown in bottom right image. Lower panel is magnification of inset box. Scale bar
= 10 m in both images.
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Figure 21. RGNEFΔL did not form granules and did not co-localize with TDP-43 following
oxidative stress with ethacrynic acid. Immunofluorescence showing localization of transfected
myc-tagged RGNEFΔL (green), endogenous TDP-43 (red) and DAPI labeling of nuclei (blue) in
HEK293T cells following exposure to 70 M of Ethacrynic acid for 5 hours. Merge of
fluorescence shown in bottom right image. Lower panel is magnification of inset box. Scale bar
= 10 m in both images.
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Figure 22. L-Rich formed granules that did not appear to co-localize with TDP-43
following oxidative stress with ethacrynic acid. Immunofluorescence showing localization of
transfected flag tagged L-Rich (green), endogenous TDP-43 (red) and DAPI labeling of nuclei
(blue) in HEK293T cells following exposure to 70 M of ethacrynic acid for 5 hours. Merge of
fluorescence shown in bottom right image. Lower panel is magnification of inset box. Arrow
denote granules. Scale bar = 10 m in both images.
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3.1.3 Immunoprecipitation
Given the apparent colocalization of L-Rich with TDP-43 observed by
immunofluorescence, we examined whether RGNEFΔL or L-Rich interacted with TDP-43. A
rabbit polyclonal TDP-43 antibody was bound to G-Sepharose beads, followed by incubation
with cell lysate of HEK293T cells transfected with the RGNEF constructs used previously
(RGNEF, RGNEFΔL or L-Rich). Following washing of columns, a Western blot was ran to
detect whether RGNEF, RGNEFΔL, or L-Rich immunoprecipitated endogenous TDP-43 (Figure
23).
We observed that TDP-43 immunoprecipitated full length RGNEF (Figure 23A). This
observation is consistent with our previous results demonstrating that TDP-43 interacts with fulllength RGNEF in HEK293T cells (Keller et al., 2012). Neither RGNEFΔL nor L-Rich were
immunoprecipitated by TDP-43 (Figure 23A, B).
Because L-Rich appeared to co-localize with TDP granules under osmotic stress
conditions (Figure 18), we stressed cells with sorbitol before protein extraction, followed by the
immunoprecipitation experiment to investigate whether TDP-43 selectively interacts with L-Rich
under this condition. Results show that despite the observation in immunofluorescence, the LRich was not immunoprecipitated by TDP-43 after osmotic stress (Figure 24). The failure to
observe this could be due to lack of sensitivity regarding the assay, where the interaction is weak
or is a transient protein-protein interaction. Further analysis using label transfer or cross-linking
assays may be warranted, as they are better suited to the potentially weak interaction that is
occurring here.
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myc-RGNEF

myc-RGNEFΔL

flag-L-Rich

Figure 23. TDP-43 immunoprecipitated myc-RGNEF but not myc-RGNEFΔL or flag-LRich alone. (A) Western blot showing the immunoprecipitation (IP) results for myc-tagged full
length RGNEF (RGNEF) and myc-tagged RGNEF lacking the L-Rich domain (RGNEFΔL). “+
lane” contains 50 g of whole protein lysate without IP showing expression of the target protein
(input). “– lane” is IP control using rabbit IgG antibody. “IP lane” is IP with rabbit α-TDP-43
antibody. Mouse α-c-myc antibody was used for probing the Western blot to detect RGNEF and
RGNEFΔL (WB: Ms α-c-myc). (B) Western blot showing the IP results for the flag-tagged LRich . “+, – and IP lanes” are as defined in A. Mouse α-flag antibody was used to detect L-Rich
domain. (WB: Ms α-Flag)
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Figure 24. TDP-43 did not immunoprecipitate flag-L-Rich from lysate of cells exposed to
osmotic stress. Western blot showing the immunoprecipitation (IP) results for flag-tagged LRich domain with added osmotic stress (400 mM Sorbitol for 4 hours) prior to protein extraction.
“+ lane” contains 100 g of whole protein lysate without IP demonstrating expression of the
transfected protein (input). “– lane” is IP control using rabbit IgG antibody. “– 1° lane” is the
control where no primary antibody was used in the IP experiment. “IP lane” is IP with rabbit αTDP-43 antibody.
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3.1

In vivo Results

3.2.1 Drosophila model
To determine if the pro-survival effect of full-length RGNEF observed in vitro and the
apparent role of the L-Rich domain could also be observed in vivo, we explored a Drosophila
transgenic model to specifically examine a potential role for L-Rich. After the selection of the
single transgenic lines for L-Rich and TDP-43, a double transgenic line carrying both transgenes
was generated using standard fly genetics. For the expression of the transgenes, the chosen driver
lines were: Elav-gal4, for pan-neuronal expression, D42-gal4 for motor neuron expression and
GMR-gal4 for expression in the eye which allowed for more direct observation of pathology. We
confirmed the presence of the transgenes in the genome of the single and double transgenic flies
(Figure 25A). Fly lines that were not used in this thesis (L-Rich line 4 and its double transgenic
with TDP-43 line 6 and TDP-43 line 9) also appear in the genomic analysis. The expression of
the transgenes on the single and double transgenic lines of line 2 L-Rich and line 6 TDP-43 using
all the drivers is shown in Figure 25B.
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Figure 25. Genomic presence and mRNA expression of TDP-43 and L-Rich in transgenic
flies. (A) An agarose gel showing genomic analysis of single transgenic carrying the Leucinerich domain coding region: L-Rich 2 and L-Rich 4, the TDP-43 coding region: TDP-43 6, TDP43 9, and double transgenic flies: L-Rich 2;TDP-43 6, L-Rich 2;TDP-43 9, L-Rich 4;TDP-43 6,
and L-Rich 4;TDP-43 9, compared to parental fly lines (w-). pcDNA-flag-Leucine-rich domain
((+) L-Rich) and pcDNA-TDP-43 plasmids were used as positive control ((+) TDP-43). RT and
PCR negative controls were incorporated ((-) RT; (-) PCR). Only L-Rich 2, TDP-43 6, and the
double transgenic line L-Rich 2;TDP-43 6 in A, L-Rich; TDP-43 in B) were further examined in
this thesis. (B) RT-PCR analysis showing RNA expression of single transgenic LeuR, TDP-43
flies and double transgenic flies L2;T6, compared to non-expressing fly lines (w-), pcDNA-flag
Leucine-rich domain- plasmid ((+) L-Rich) and pcDNA-TDP-43 plasmid ((+) TDP-43) were
used as positive controls, and RT and PCR negative controls ((-) RT; (-) PCR) were
incorporated.

65
3.2.2 Lifespan
To investigate what effect L-Rich might have on longevity, single transgenic fly lines
containing L-Rich, or TDP-43, or both (L-Rich; TDP-43) were crossed with either a pan
neuronal driver (Elav-gal4) or a motor neuron specific driver (D42-gal4) for expression of the
transgenes. Male progeny were collected and analyzed for lifespan where death events were
recorded until no fly remained. The data are represented using Kaplan-Meier survival curves.
Mantel-Cox test was used for statistical analysis.
For pan-neuronally expressing transgenic flies, L-Rich on its own (Elav-L-Rich)
conferred a significant improvement in lifespan, compared to the parental fly line crossed with
the Elav driver (Elav-w-) and the non-expressing fly line (L-Rich control) (Figure 26B). Human
wild-type TDP-43 when expressed alone (Elav-TDP-43) conferred a significant reduction in
lifespan compared to driver control and the non-expressing fly line (Figure 26C). When LeuR
and TDP-43 are expressed together in the double transgenic fly line (Elav-L-Rich; TDP-43),
there was a significant improvement in lifespan compared to the non-expressing control and
driver control (Figure 26D). Additionally, the double transgenic showed a significant increase in
lifespan compared to the single transgenic TDP-43 flies (Figure 26A).
When fly lines were crossed with the motor neuron specific driver (D42-gal4) (Figure
27), L-Rich alone (D42-L-Rich) continued to show a significant increase in lifespan compared to
both controls (D42-w-, L-Rich control) (Figure 27B). Single transgenic TDP-43 flies showed a
significant decrease in lifespan compare to both controls (p=<0.0001, p=<0.0001) (Figure 27C).
The double transgenic fly line (D42-L-Rich; TDP-43) did not show significant change in lifespan
compared to the driver control line (p=0.4688) or the non-expressing fly line (p=0.4085) (Figure
27D) but did show significant improvement in survival duration compared to the single
transgenic TDP-43 flies (p=<0.0001) (Figure 27A).
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Figure 26. Flies expressing the Leucine-rich domain of RGNEF and TDP-43 showed an
increased lifespan compared to single transgenic TDP-43. (A) Lifespan analysis of panneuronally expressed L-Rich (Elav-L-Rich; N = 117), TDP-43 (Elav-TDP-43; N=88) as well as a
double transgenic flies expressing both together (Elav-L-Rich; TDP-43; N=107) and the Elav
driver crossed with the parental fly line (Elav-w-) as control (N = 87). (B) Lifespan analysis of
pan-neuronally expressed L-Rich (Elav-L-Rich; N= 117), the Elav driver crossed with the
parental fly line (Elav-w-) and non-expressing fly line as controls (L-Rich Control; N = 87). (C)
Lifespan analysis of pan-neuronally expressed TDP-43 (Elav-TDP-43; N= 88), the Elav driver
crossed with the parental fly line (Elav-w-) and non-expressing fly line as controls (TDP-43
Control; N = 60). (D) Lifespan analysis of pan-neuronally expressed double transgenic L-Rich;
TDP-43 fly line (Elav-L-Rich; TDP-43; N= 107), the Elav driver crossed with the parental fly
line (elav-w-) and non-expressing fly line as controls (L-Rich; TDP-43 Control; N = 49). All data
was collected at the same time; Figures B, C, and D are derivations of A and thus are not
representative of new data. Median Survival (days): Elav-w-=70, Elav-TDP-43= 2, Elav-LRich=70, Elav-L-Rich;TDP-43=75, L-Rich control=60, TDP-43 Control=35, L-Rich;TDP-43
control=45. ****=p<0.0001.

67

Figure 27. Flies expressing the Leucine-rich domain of RGNEF and TDP-43 showed an
increased lifespan compared to single transgenic TDP-43. (A) Lifespan analysis of motorneuron specifically expressed L-Rich (D42-L-Rich; N = 87), TDP-43 (D42-TDP-43; N=92) as
well as a double-transgenic flies expressing both together (D42-L-Rich; TDP-43; N=31) and the
D42 driver crossed with the parental fly line (D42-w-) as control (N = 28). (B) Lifespan analysis
of motor-neuron specifically expressed L-Rich (Elav-L-Rich; N= 117), the D42 driver crossed
with the parental fly line (Elav-w-) and the non-expressing fly line as controls (L-Rich Control; N
= 87). (C) Lifespan analysis of motor-neuron specifically expressed TDP-43 (D42-TDP-43; N=
92), the D42 driver crossed with the parental fly line (D42-w-; N = 28) and the non-expressing
fly line as controls (TDP-43 Control; N = 60). (D) Lifespan analysis of motor-neuron specifically
expressed double transgenic L-Rich; TDP-43 fly line (D42-LeuR; TDP-43; N= 31), the D42
driver crossed with the parental fly line (D42-w-; N = 28) and the non-expressing fly line as
controls (L-Rich; TDP-43 Control; N = 49). All data was collected at the same time; Figures B,
C, and D are derivations of A and thus do not contain new data. Median Survival (days): D42-w=52.5, D42-TDP-43=15, D42-L-Rich=70, D42-L-Rich-TDP-43=50, L-Rich Control=60, TDP43 Control=35, L-Rich; TDP-43 Control= 45. ns=not significant. ****=p<0.0001.
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3.2.3 Climbing assay
To complement the lifespan analysis, motor function was assessed through a climbing
assay in which flies were tapped to the bottom of a parafilm sealed cylinder that was divided into
4 quadrants. Flies were allowed to climb for a set period of time and the number of flies in each
quadrant after 10 seconds was recorded. A climbing index was calculated based on the number
of flies in each quadrant. Non-expressing fly lines containing the transgene of interest for each
group acted as control.
For flies that were crossed with the pan-neuronal driver (Elav-gal4), L-Rich expression
alone (Elav-L-Rich) conferred no significant difference in motor function compared to control
(L-Rich control) at day 1 and day 5 (Figure 28A & B). TDP-43 expression (Elav-TDP-43)
conferred a significant motor deficit compared to non-expressing control (TDP-43 control) at day
1 and day 5 (p=<0.0001). The double transgenic flies (Elav-L-Rich; TDP-43) conferred no
significant difference compared to non-expressing control lines (Elav-L-Rich; TDP-43 control)
but did show significant inhibition of motor deficit compared to TDP-43 single transgenic
expression at day 1 and day 5 (p=<0.0001). Day 5 was the final day as no single transgenic TDP43 lived past this date.
When crossed with the motor neuron specific driver (D42-gal4), at day 5 there was no
significant difference between control groups and expressing fly lines (Figure 28C). At day 10
however, the single transgenic TDP-43 fly line (D42-TDP-43) showed a significant motor deficit
compared to the TDP-43 control line (TDP-43 control) (p=0.0274) (Figure 28D). Also, on day
10, the double transgenic fly line (D42-L-Rich; TDP-43) showed significant suppression of
motor deficit compared to the single transgenic TDP-43 fly line. L-Rich expressed alone (D42-LRich) showed no significant difference compared to control (L-Rich control).
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Figure 28. L-Rich expression reduced motor deficit induced by TDP-43. Climbing assay
showing day 1 (A) and day 5 (B) motor function of pan-neuronal expressing-double transgenic
flies (Elav-L-Rich; TDP-43; n=30), single transgenic TDP-43 (Elav-TDP-43, n=30) and L-Rich
(Elav-L-Rich; n=160) flies and non-expressing TDP-43 and L-Rich flies as controls (TDP-43, LRich, and L-Rich;TDP-43 Control; n=30 each). B Climbing assay showing day 5 (C) and day 10
(D) motor function of motor neuron-specifically expressing double transgenic leucine-rich
domain and TDP-43 flies (D42-L-Rich;TDP-43; n=80), single transgenic TDP-43 and L-Rich
flies (D42-TDP-43; n=100, , D42- L-Rich; n=50) and non-expressing TDP-43 flies as control
(TDP-43 Control, L-Rich Control and LeuR;TDP-43 Control; n=30 each). **** = p<0.0001.
Data presented as mean + standard error.
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3.2.4 Eye Expression/ Degeneration
To further complement the phenotypic analysis of the Drosophila lines, transgenic lines
were crossed with the GMR-gal4 driver line that selectively expressed the transgene in the eye.
All male progeny were collected and pictures were taken of their eyes each week for up to 8
weeks. The goal was to observe for any degeneration that might arise from the presence of LRich alone, TDP-43 alone, or both expressed together (Figure 29). Weeks 2 to 5 are shown as
natural aging processes begin to confound any observation made after this time. The parental fly
line (w-) crossed with the GMR-gal4 driver acted as control.
L-Rich, when expressed alone, appeared to show no structural changes, degradation, or
cell death around the outer rim of the eye, similar to control (GMR-w-). At week 5 however,
there was evidence of some cell death around the outer rim, whereas the control group continued
to show none. This could be a random effect of aging and not due to the expression of L-Rich.
TDP-43 when expressed alone demonstrated characteristic necrosis of the inner eye and cell
death around the outer rim of the eye and both transgenic fly lines investigated from week 1.
This progressed in severity over the following weeks with more structural deformation,
discoloration and cell death being observed in weeks 3, 4 and 5.
In the double transgenic fly lines (L-Rich; TDP-43), a phenotype similar to the single
transgenic TDP-43 was observed from week 1. The severity of the progression appears to have
been less, though further investigation into the changes in internal structure of the eye following
expression is warranted. Quantification of surface eye degeneration and examination of the inner
structure of the eye would help to consolidate these preliminary observations.
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Figure 29. Leucine-rich domain of RGNEF decreases eye degeneration of TDP-43 in flies
with eye specific expression. Representative images of eye specific expression of the Leucinerich domain (L-Rich; n=3, N = 60), TDP-43 (TDP-43; n=3 N = 45) and the double transgenic
line expressing both (L-Rich; TDP-43; n=3, N = 60), compared to the GMR driver crossed with
the parental line as control (w-; n=3 N=60). At least 5 images were taken for each group per
biological replicate. Images were taken every 7 days.
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Chapter 4
4.1

Discussion

This master’s thesis sought to elucidate the role of L-Rich towards the protective function of
full length RGNEF in vitro and its potentially protective role in modulating TDP-43 toxicity in
vivo. Following analysis, L-Rich appears essential for the protective effect of full-length RGNEF
under specific stress conditions in vitro and protects against TDP-43 toxicity in vivo.
Previously, we showed that a GST-tagged fragment of RGNEF immunoprecipitated NEFL
mRNA from ALS spinal cord homogenates. This supported the hypothesis that RGNEF was
involved in the dysregulation of neurofilament stoichiometry observed in ALS (Volkening et al.,
2010; Wong et al., 2000). We then observed that RGNEF was not only an RNA binding protein,
binding to and destabilizing NEFL mRNA, but also a guanine exchange factor (Droppelmann et
al., 2013a). RGNEF was also shown in ALS tissue to co-localize with TDP-43 and FUS/TLS,
both of which are ALS-linked RNA-binding proteins (Droppelmann et al., 2013b; Keller et al.,
2012). When characterizing its functions, RGNEF was discovered to have a pro-survival role
under osmotic and oxidative stress conditions in vitro (Cheung et al., 2017).
When co-expressing RGNEF with either wild type or A315T mutated TDP-43 in HEK239T
cells, RGNEF significantly reduced the toxicity of both TDP-43 variants (C Droppelmann,
unpublished data). In addition, when co-expressing different RGNEF constructs, L-Rich was the
only construct that was observed to not only aggregate, but co-aggregate with endogenous TDP43 in HEK293T cells under metabolic stress conditions (C Droppelmann, unpublished data).
In this thesis, L-Rich (an amino-terminal fragment of RGNEF containing a Leucine-rich
domain) and its interaction with TDP-43 was investigated not only in vitro using HEK293T cells
but in vivo in a D. melanogaster model. A TDP-43 fly model was particularly useful as it had
been well established in the literature to produce a consistent motor and cellular phenotype in
flies (Feiguin et al., 2009; Langellotti et al., 2016; Li et al., 2010; Romano et al., 2012; Wang et
al., 2011). The wildtype form of TDP-43 was chosen over mutated forms as it was shown to
produce a greater neurodegenerative phenotype when overexpressed in flies (Voigt et al., 2010).
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The goal of my in vitro analyses was to elucidate whether L-Rich was essential for the
protective effect of RGNEF and its interaction with TDP-43. The goal of the in vivo analyses
was to elucidate what phenotypic effect L-Rich might have alone, or when co-expressed with
wild type TDP-43, on motor function, lifespan and eye degeneration of flies. Dr. Cristian
Droppelmann at the Strong Lab investigated full-length RGNEF in parallel with my work. The
overall goal was to characterize the protective modifying role of RGNEF towards TDP-43
toxicity.
Table 7 summarizes the observations made in this thesis, with the inclusion of observations
made by Dr. Droppelmann in his investigation of full-length RGNEF in the same Drosophila
model. In the cytotoxicity assay, we observed that in the absence of external stress conditions, all
constructs of RGNEF (full length RGNEF, RGNEFΔL, L-Rich) significantly increased cell
viability compared to control. Under osmotic stress (400 mM sorbitol, 4 hours), both full length
RGNEF and RGNEFΔL significantly enhanced cell viability. In contrast, only full length
RGNEF enhanced cell viability in response to oxidative stress (70 M ethacrynic acid, 5 hours).
In immunofluorescence, in absence of an external cellular stress, RGNEF and RGNEFΔL was
observed to be pre-dominantly localized to the cytoplasm in HEK293T cells. We observed
similar cytoplasmic localization with some granule formation for L-Rich. Under osmotic stress
conditions, we observed that RGNEF and L-Rich formed granules that co-localized with TDP-43
immunoreactive granules. RGNEFΔL also formed granules that co-localized with TDP-43 under
these same conditions, but only to a minimal extent. Under oxidative stress conditions, none of
the constructs co-localized with TDP-43 granules. RGNEF and RGNEFΔL did not form
granules, but localized evenly throughout the cytoplasm. L-Rich on the other hand, formed
granules but these granules did not co-localize with TDP-43 granules.
In immunoprecipitation studies, we observed that TDP-43 immunoprecipitated RGNEF but
not RGNEFΔL or L-Rich. Under osmotic stress conditions, despite the observed co-localization
in immunofluorescence, TDP-43 did not immunoprecipitate L-Rich.
In the Drosophila melanogaster model, we observed that L-Rich conferred significant
protection against TDP-43 toxicity in all experiments. Regarding motor function, the coexpression of L-Rich with TDP-43 led to a significant decrease of the impairment observed in
flies expressing TDP-43 alone. This relationship persisted when assessing lifespan, where the
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double transgenic fly line showed a significant increase in lifespan compared to flies expressing
TDP-43 alone. Lastly, the early appearance of eye degeneration was delayed when co-expressing
L-Rich with TDP-43 in the eye. These findings mirrored those observed for full length RGNEF,
completed by Dr. Droppelmann. When co-expressed with TDP-43, RGNEF significantly
increased lifespan, inhibited motor deficit, and delayed eye degeneration compared to flies
expressing TDP-43 alone (unpublished data). Based on these findings, it is clear that L-Rich
plays a role under oxidative stress in vitro and against TDP-43 toxicity in vivo.
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Table 7: Summary of results.
Experiment

Condition

RGNEF

RGNEFΔL

L-Rich

Cytotoxicity

No stress

+

+

+

+ = protective

Osmotic

+

+

-

- = not protective

Oxidative

+

-

-

Immunofluorescence

No stress

-

-

-

+ = co-localize with TDP-43 granules

Osmotic

+

+*

+

Oxidative

-

-

-

No stress

+

-

-

Osmotic

NA

NA

-

Oxidative

NA

NA

NA

Single

+

NA

+

Double

+

NA

+

Single

-

NA

-

Double

+

NA

+

Single

-

NA

-

Double

+

NA

+

- = no co-localization
* = co-localize to a minimal extent
TDP-43 IP
+ = IP by endogenous TDP-43
- = no IP by endogenous TDP-43
NA = not available
Lifespan
+ = increased lifespan
- = no increase in lifespan
NA = not available
Motor Function
+ = inhibition of TDP-43 motor deficit
- = no inhibition of TDP-43 motor deficit
NA = not available
Eye expression
+ = inhibition of TDP-43 eye degeneration
- = no inhibition of TDP-43 degeneration
NA = not available

RGNEF Drosophila Data produced by Cristian Droppelmann.
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The in vitro experiments suggest that the L-Rich domain is critical for the protective effect of
RGNEF but only under specific conditions. Under oxidative stress, RGNEFΔL does not produce
a significant increase in cell viability. In concert with the observation that L-Rich alone also does
not confer protection, this suggests that the intact protein is needed to protect the cells under
oxidative stress. It is possible that a specific structural conformation of RGNEF may be
necessary to produce protection under these conditions and this may be modified by the nature of
the stressor. Interestingly, L-Rich appears critical for the protective effect of RGNEF under
oxidative conditions. In contrast, under osmotic stress, RGNEFΔL does confer protection. This
would suggest that L-Rich is not critical for the protective effect of RGNEF under osmotic stress
conditions and that RGNEFΔL is sufficient to reproduce this effect. Under non-stress conditions,
RGNEFΔL showed a significant increase in cell viability, suggesting L-Rich is not critical under
this condition either.
The specific importance of L-Rich observed under distinct stress conditions could relate to
how oxidative stress and osmotic stress uniquely effect the cell. Oxidative stress occurs by the
accumulation of reactive oxygen species, which are detoxified by either non-enzymatic
mechanisms, through glutathione or thioredoxin, or enzymatic mechanisms via superoxide
dismutases, peroxidases and catalases. Osmotic stress, on the other hand, is associated with a
water imbalance between the cell and its environment. This leads to a response through
aquaporins and electrolyte transporters (Mager et al., 2000). As RGNEF produces a significant
protection under both stress conditions, L-Rich may participate only in the response that relates
to oxidative and not to osmotic stress. Under non-stress conditions, RGNEF and RGNEFΔL
showed a significant increase in cell viability, suggesting L-Rich was not critical under this
condition either. L-Rich alone was able to confer a significant increase in survival on its own,
which, due to the findings from the different stress conditions, suggests that the survival effect of
L-Rich is not the same survival effect of full length RGNEF. How L-Rich confers an increased
survival on its own remains unclear.
The immunoprecipitation experiment results suggest that L-Rich is a key participant in the
interaction between RGNEF and TDP-43, but that L-Rich is not solely responsible for this
interaction. Given that RGNEFΔL is not immunoprecipitated by TDP-43, a particular structural
conformation of full-length RGNEF, lost when deleting the amino terminal region, may be
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necessary for the interaction. Another region of RGNEF may require L-Rich to facilitate the
interaction with TDP-43 either directly or indirectly via some intermediate molecule.
In immunofluorescence, under osmotic stress conditions, RGNEF and L-Rich co-localized
with TDP-43 immunoreactive granules, while RGNEFΔL did to a minimal extent. This suggests
that L-Rich is important in the localization of RGNEF in TDP-43 positive granules. Although
most of RGNEFΔL does not co-localize with TDP-43 positive granules, it may be that
RGNEFΔL might co-localize with a different typical granule. Staufen-1, a common transport
granule marker, has been shown to co-localize with RGNEF under osmotic stress conditions and
therefore may be useful to investigate in the future (Cheung et al., 2017).
Under oxidative stress, we observed that none of the RGNEF constructs co-localize with
TDP-43 immunoreactive granules. We also observed that only L-Rich immunoreactive granules
are formed. Morphological defects are also apparent for cells expressing RGNEF and RGNEFΔL
but not L-Rich. TDP-43 immunoreactive granules continued to form none the less. This suggests
that ethacrynic acid, a glutathione inhibitor, has somehow disrupted the formation of RGNEF
and RGNEFΔL immunoreactive granules and has disrupted the structure of the cell. Despite this
observation, RGNEF produces a protective effect under oxidative stress conditions. This would
suggest that granule formation is not necessary for RGNEF to produce protection. Granule
formation up to this point may have been assumed to be necessary for protection against stress.
With RGNEF producing a protective effect under oxidative stress, while not forming granules in
immunofluorescence, it indicates granule formation may not be necessary for this function
The lack of granules formed by RGNEF under ethacrynic acid induced oxidative stress
differs from that reported under sodium arsenite induced oxidative stress (Cheung et al., 2017).
A key difference between these two stressors is the pathway they take to induce their stress.
Ethacrynic acid inhibits glutathione, while sodium arsenite disrupts superoxide dismutase and
peroxidase levels leading to increased reactive oxygen species production and mitochondrial
membrane proliferation. This could mean that the protective effect of RGNEF occurs
downstream to the steps these stressors influence, since RGNEF is also protective against sodium
arsenite oxidative stress (Cheung et al., 2017).
Additional cell lines would also be useful to investigate RGNEF in vitro. HEK293T cells,
despite expressing neurofilament, are not neuronal cells. IPSC derived motor neurons or SH-
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SY5Y human neuroblastoma cells may help to clarify the potential protective effect these
constructs might have on cells affected by TDP-43. What will also be needed is an investigation
into the co-expression of L-Rich with TDP-43 in vitro. This would complement the coexpression of L-Rich and TDP-43 done in Drosophila and would help to consolidate the findings
made there.
The Drosophila model data shows that L-Rich is a protective modifier of TDP-43 toxicity.
The mechanism underlying how this protective effect comes about and whether it comes about
through pathways that are native to RGNEF will need to be investigated further. Since fulllength RGNEF and L-Rich are conferring similar benefit, a complementary experiment that
would help to clarify the importance of L-Rich for RGNEF is the investigation of RGNEFΔL in
the same model. With the L-Rich producing a protective effect alone, similar to the cytotoxicity
assay under non-stressed conditions, L-Rich may be acting through a unique RGNEF function.
What that pathway is remains unclear. Elucidating the role of L-Rich may also be done by
conducting mass spectrometry of interactors of full length RGNEF and RGNEFΔL. The
difference between the profile of the two would highlight where L-Rich is important for RGNEF.
To date, modifiers have been found that either improve or worsen the phenotype induced by
TDP-43. Ubiquilin 1 and FUS/TLS, both ALS related proteins, have been shown to negatively
modify lifespan and motor function deficit in a Drosophila model expressing human TDP-43
(Hanson et al., 2010; Lanson et al., 2011). Notch pathway mutations, as well as mutations in
Nucleoporin protein 50 extend the lifespan of transgenic TDP-43 flies in which the expression is
restricted to motor neurons (Zhan et al., 2013). Mutations in ITPR1, an endoplasmic reticulum
calcium channel receptor also improve lifespan and motor function in flies (Kim et al., 2012).
Never before has a fragment of a protein been investigated, let alone found to positively modify
TDP-43 toxicity. Besides lifespan and motor function deficit, TDP-43 is known to change the
gene expression pattern of various genes when expressed in flies (Zhan et al., 2013). L-Rich may
influence the expression change induced by TDP-43. Micro array analysis of the single
transgenic L-Rich fly line alongside the double transgenic fly line may best answer this question.
L-Rich, which is the amino terminal fragment of RGNEF that contains a Leucine-rich
domain, does not solely contain a Leucine-rich domain. Ankyrin repeats are also present that lie
C-terminal to the Leucine-rich domain. Future experiments will need to investigate these two
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regions separately to effectively characterize their roles regarding full-length RGNEF. For
example, further analyzing in vitro analyses using the L-Rich fragment with the ankyrin repeats
removed, or the Ankyrin repeats alone with the Leucine-rich domain removed. Given the
potential importance of the structure of RGNEF for conferring its effects, uncovering the 3D
structure of RGNEF would help immensely in clarifying how its domains relate or interact to one
another and how, through removal of L-Rich, this relation is disrupted. The reversal of the
immunoprecipitation experiment had been attempted, where the constructs of RGNEF were
bound to G-Sepharose beads to see whether they would successfully immunoprecipitate
endogenous TDP-43 from HEK293T cells. However, inconsistent results were obtained where
TDP-43 was detected in the negative control. What remains to be known is whether RGNEF and
TDP-43 interact directly or indirectly by some intermediate protein. If full-length RGNEF could
be purified and studied through other protein-protein interaction experiments coupled to mass
spectrometry, then one could potentially uncover whether an intermediate protein, or a protein
complex of some kind is necessary for the observed interaction between the two. Given the
observation that L-Rich and RGNEFΔL co-localize with TDP-43 in immunofluorescence, their
interaction with TDP-43 may be transient or weak. If so, cross-linking assays may be useful to
better understand the interaction between RGNEF and TDP-43.
Images shown for the eye specific expression of L-Rich co-expressed with TDP-43
demonstrate a slight reduction in degeneration. There appears to be proper development of the
eye in the double transgenic flies, whereas TDP-43 shows structural defects, necrosis, and loss of
ommatidia. This toxicity induced by human wildtype TDP-43 is consistent with literature (Estes
et al., 2011; Li et al., 2010) TDP-43 has been shown to induce retinal degeneration within the
eye when expressed through the GMR driver (Estes et al., 2011). Therefore, hematoxylin
staining would help to clarify whether L-Rich has modified this internal degeneration as well.
Scanning electron microscopy, along with quantification of ommatidia degeneration would also
help to consolidate the preliminary observations made towards toxicity observed in the eye.
TDP-43 has also been shown to induce morphological defects at the neural muscular junction
synapse, neuronal cell death of mushroom bodies, as well as aggregate formation in the motor
neurons and retinal discs of Drosophila (Estes et al., 2011; Li et al., 2010). Investigating these
regions through immunohistochemistry would help to uncover whether L-Rich and RGNEF have
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influenced this phenotype as well. What also remains to be done is quantification of RNA, via
quantitative PCR, and protein expression via protein extraction and western blot of all transgenic
fly lines. This is necessary to address the possibility that TDP-43 expression is reduced when coexpressed with L-Rich. This could then explain why there is reduced toxicity as TDP-43 has
been shown to produce toxicity in a dose-dependent manner (Estes et al., 2011; Li et al., 2010;
Ritson et al., 2010; Voigt et al., 2010).
An additional approach that could have been utilized to introduce our transgenes of
interest is targeted insertion. Through this method, the transgene is randomly inserted into
pseudo-attP sites present in the Drosophila genome (Fish et al., 2007). This leads to the
understanding that the transgene exists in a known insertion site. P-element mediated random
insertion, the method used in this thesis, has the limitation that one does not know where the
gene has inserted in the chromosome of interest. This allows for the possibility that the transgene
lies outside of the region protected by balancers, leaving it susceptible to recombination events.
To address this, we worked with stable balanced lines received from BestGene. Further
balancing performed in this thesis would not affect the integrity of the transgene as the same
balancers used to generate the stable balanced lines were used to generate the double transgenic
fly line. The transgene therefore remained within a balanced region where recombination could
not have occurred. Transgenic integrity was also confirmed experimentally with the
demonstration of genomic presence and mRNA expression of both transgenes in the double
transgenic line (Figure 25). Lastly, with the non-expressing double transgenic fly line producing
no observable effect on lifespan, motor function and eye degeneration (with the minimal eye
degeneration being just as likely a TDP-43 related phenotype), it is unlikely that the protective
effect observed here is a recombination phenotype.
Overall, the relationship between RGNEF and TDP-43 is gradually becoming clear.
Depending on how the Leucine-rich domain confers its protective modification of TDP-43, one
could potentially take advantage of this domain, or the minimal protective unit within, that is
necessary for the protective effect as a therapeutic target. Pending further investigation, those
afflicted by ALS may yet have a new drug to look forward to.
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